Daratumumab Clinical Trials (2026): 347 Studies for Multiple Myeloma & Plasma Cell Myeloma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
347 Daratumumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 115 indications (including Multiple Myeloma & Plasma Cell Myeloma) and 54,064 total planned enrollment. 57 Phase 3 Daratumumab trials and 161 Phase 2, 7 Phase 4 are listed. 104 Daratumumab clinical trials are actively recruiting at 1,512 U.S. sites across 50 states. Most recent activity: NCT06358638 (Sep 2054).
Where to Participate: All Daratumumab Trial Sites in the U.S. (1,512 sites across 50 states)
Every actively recruiting Daratumumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama at Birmingham | Birmingham35205 | NCT06615479 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294 | NCT06974786 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT03937635 | Map |
| AL | University of Alabama At Birmingham Hospital | Birmingham35294-0004 | NCT04973605 | Map |
| AL | GSK Investigational Site | Mobile36607 | NCT06679101 | Map |
| AK | Alaska Breast Care and Surgery LLC | Anchorage99508 | NCT03937635 | Map |
| AK | Alaska Breast Care and Surgery LLC | Anchorage99508 | NCT05561387 | Map |
| AK | Alaska Oncology and Hematology LLC | Anchorage99508 | NCT03937635 | Map |
| AK | Alaska Oncology and Hematology LLC | Anchorage99508 | NCT05561387 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT03937635 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT05561387 | Map |
| AK | Anchorage Associates in Radiation Medicine | Anchorage98508 | NCT03937635 | Map |
| AK | Anchorage Associates in Radiation Medicine | Anchorage98508 | NCT05561387 | Map |
| AK | Anchorage Oncology Centre | Anchorage99508 | NCT05561387 | Map |
| AK | Anchorage Radiation Therapy Center | Anchorage99504 | NCT05561387 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT03937635 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT05561387 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT03937635 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT05561387 | Map |
| AK | Fairbanks Memorial Hospital | Fairbanks99701 | NCT03937635 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT05552222 | Map |
| AZ | CTCA at Western Regional Medical Center | Goodyear85338 | NCT03937635 | Map |
| AZ | CTCA at Western Regional Medical Center | Goodyear85338 | NCT06022939 | Map |
| AZ | Kingman Regional Medical Center | Kingman86401 | NCT03937635 | Map |
| AZ | Cancer Center at Saint Joseph's | Phoenix85004 | NCT03937635 | Map |
| AZ | Cancer Center at Saint Joseph's | Phoenix85004 | NCT04566328 | Map |
| AZ | Cancer Center at Saint Joseph's | Phoenix85004 | NCT05561387 | Map |
| AZ | GSK Investigational Site | Phoenix85054 | NCT06679101 | Map |
| AZ | Mayo Clinic Hospital Scottsdale /ID# 278349 | Scottsdale85259 | NCT07095452 | Map |
| AZ | Mayo Clinic in Arizona | Scottsdale85259 | NCT05898646 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT06022939 | Map |
| AZ | University of Arizona Cancer Center | Tucson85719 | NCT05552222 | Map |
| AZ | University of Arizona Cancer Center-North Campus | Tucson85719 | NCT06022939 | Map |
| AR | Mercy Hospital Fort Smith | Fort Smith72903 | NCT03937635 | Map |
| AR | Mercy Hospital Fort Smith | Fort Smith72903 | NCT04566328 | Map |
| AR | Mercy Hospital Fort Smith | Fort Smith72903 | NCT05561387 | Map |
| AR | CARTI Cancer Center | Little Rock72205 | NCT04566328 | Map |
| AR | CARTI Cancer Center | Little Rock72205 | NCT05561387 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT05561387 | Map |
| CA | Mission Hope Medical Oncology - Arroyo Grande | Arroyo Grande93420 | NCT03937635 | Map |
| CA | Mission Hope Medical Oncology - Arroyo Grande | Arroyo Grande93420 | NCT04566328 | Map |
| CA | Mission Hope Medical Oncology - Arroyo Grande | Arroyo Grande93420 | NCT05561387 | Map |
| CA | PCR Oncology | Arroyo Grande93420 | NCT03937635 | Map |
| CA | GSK Investigational Site | Beverly Hills90211 | NCT06679101 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT03937635 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT05561387 | Map |
| CA | Marshall Cancer Center | Cameron Park95682 | NCT05561387 | Map |
| CA | Mercy Cancer Center - Carmichael | Carmichael95608 | NCT03937635 | Map |
| CA | Mercy Cancer Center - Carmichael | Carmichael95608 | NCT04566328 | Map |
| CA | Mercy Cancer Center - Carmichael | Carmichael95608 | NCT05561387 | Map |
| CA | Mercy San Juan Medical Center | Carmichael95608 | NCT03937635 | Map |
| CA | Mercy San Juan Medical Center | Carmichael95608 | NCT04566328 | Map |
| CA | Mercy San Juan Medical Center | Carmichael95608 | NCT05561387 | Map |
| CA | UCSF Fresno | Clovis93611 | NCT05552222 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT06022939 | Map |
| CA | City of Hope Duarte | Duarte91010 | NCT05552222 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT05363111 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06287944 | Map |
| CA | City of Hope National Medical Center | Duarte91010-3012 | NCT04973605 | Map |
| CA | City of Hope National Medical Center | Duarte91010-3012 | NCT07555938 | Map |
| CA | Mercy Cancer Center - Elk Grove | Elk Grove95758 | NCT03937635 | Map |
| CA | Mercy Cancer Center - Elk Grove | Elk Grove95758 | NCT04566328 | Map |
| CA | Mercy Cancer Center - Elk Grove | Elk Grove95758 | NCT05561387 | Map |
| CA | City of Hope - Lennar Foundation Cancer Center | Irvine92618 | NCT07555938 | Map |
| CA | City of Hope at Irvine Lennar | Irvine92618 | NCT06022939 | Map |
| CA | City of Hope Irvine Lennar | Irvine92618-2377 | NCT04973605 | Map |
| CA | City of Hope Orange County Lennar Foundation Cancer Center | Irvine92618 | NCT05552222 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT06022939 | Map |
| CA | Scripps Clinic Torrey Pines | La Jolla92037 | NCT05137054 | Map |
| CA | Loma Linda University Children's Hospital | Loma Linda92354 | NCT04972942 | Map |
| CA | Cancer and Blood Specialty Clinic | Los Alamitos90720 | NCT05552222 | Map |
| CA | Cedars-Sinai Medical Center /ID# 278238 | Los Angeles90048 | NCT07095452 | Map |
| CA | UCLA Hematology/Oncology - Santa Monica | Los Angeles90404 | NCT06615479 | Map |
| CA | University of Southern California /ID# 272414 | Los Angeles90033 | NCT06953960 | Map |
| CA | Valkyrie Clinical Trials | Los Angeles90067 | NCT05552222 | Map |
| CA | Valkyrie Clinical Trials | Los Angeles90670 | NCT06119685 | Map |
| CA | Contra Costa Regional Medical Center | Martinez94553-3156 | NCT03937635 | Map |
| CA | Fremont - Rideout Cancer Center | Marysville95901 | NCT05561387 | Map |
| CA | Mercy Cancer Center | Merced95340 | NCT04566328 | Map |
| CA | Mercy UC Davis Cancer Center | Merced95340 | NCT05561387 | Map |
| CA | Providence Queen of The Valley | Napa94558 | NCT05561387 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT06022939 | Map |
| CA | University of California, Irvine (UCI) Health - UC Irvine Medical Center | Orange92868 | NCT06615479 | Map |
| CA | GSK Investigational Site | Pasadena91105 | NCT06679101 | Map |
| CA | Mercy Cancer Center - Rocklin | Rocklin95765 | NCT03937635 | Map |
| CA | Mercy Cancer Center - Rocklin | Rocklin95765 | NCT04566328 | Map |
| CA | Mercy Cancer Center - Rocklin | Rocklin95765 | NCT05561387 | Map |
| CA | Mercy Cancer Center - Sacramento | Sacramento95816 | NCT03937635 | Map |
| CA | Mercy Cancer Center - Sacramento | Sacramento95816 | NCT04566328 | Map |
| CA | Mercy Cancer Center - Sacramento | Sacramento95816 | NCT05561387 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT05561387 | Map |
| CA | University of California | San Francisco94143 | NCT04972942 | Map |
| CA | Pacific Central Coast Health Center-San Luis Obispo | San Luis Obispo93401 | NCT03937635 | Map |
| CA | Pacific Central Coast Health Center-San Luis Obispo | San Luis Obispo93401 | NCT04566328 | Map |
| CA | Pacific Central Coast Health Center-San Luis Obispo | San Luis Obispo93401 | NCT05561387 | Map |
| CA | Mission Hope Medical Oncology - Santa Maria | Santa Maria93444 | NCT03937635 | Map |
| CA | Mission Hope Medical Oncology - Santa Maria | Santa Maria93444 | NCT04566328 | Map |
| CA | Mission Hope Medical Oncology - Santa Maria | Santa Maria93444 | NCT05561387 | Map |
| CA | Providence Medical Foundation - Santa Rosa | Santa Rosa95403 | NCT05561387 | Map |
| CA | Providence Santa Rosa Memorial Hospital | Santa Rosa95405 | NCT05561387 | Map |
| CA | Saint Joseph's Medical Center | Stockton95204 | NCT03937635 | Map |
| CA | Saint Joseph's Medical Center | Stockton95204 | NCT04566328 | Map |
| CA | Gene Upshaw Memorial Tahoe Forest Cancer Center | Truckee96161 | NCT05561387 | Map |
| CA | BASS Medical Group - Lennon | Walnut Creek94598 | NCT03937635 | Map |
| CA | Woodland Memorial Hospital | Woodland95695 | NCT03937635 | Map |
| CA | Woodland Memorial Hospital | Woodland95695 | NCT04566328 | Map |
| CA | Woodland Memorial Hospital | Woodland95695 | NCT05561387 | Map |
| CO | GSK Investigational Site | Aurora80012 | NCT06679101 | Map |
| CO | Rocky Mountain Cancer Centers-Aurora | Aurora80012 | NCT03937635 | Map |
| CO | Rocky Mountain Regional VA Medical Center | Aurora80045 | NCT05561387 | Map |
| CO | Boulder Community Foothills Hospital | Boulder80303 | NCT03937635 | Map |
| CO | Rocky Mountain Cancer Centers-Boulder | Boulder80304 | NCT03937635 | Map |
| CO | Penrose-Saint Francis Healthcare | Colorado Springs80907 | NCT03937635 | Map |
| CO | Penrose-Saint Francis Healthcare | Colorado Springs80907 | NCT04566328 | Map |
| CO | Penrose-Saint Francis Healthcare | Colorado Springs80907 | NCT05561387 | Map |
| CO | Rocky Mountain Cancer Centers-Penrose | Colorado Springs80907 | NCT03937635 | Map |
| CO | Rocky Mountain Cancer Centers-Penrose | Colorado Springs80907 | NCT04566328 | Map |
| CO | Rocky Mountain Cancer Centers-Penrose | Colorado Springs80907 | NCT05561387 | Map |
| CO | Saint Francis Cancer Center | Colorado Springs80923 | NCT03937635 | Map |
| CO | Saint Francis Cancer Center | Colorado Springs80923 | NCT04566328 | Map |
| CO | Saint Francis Cancer Center | Colorado Springs80923 | NCT05561387 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT06974786 | Map |
| CO | Colorado Blood Cancer Institute /ID# 273129 | Denver80218 | NCT06892522 | Map |
| CO | Colorado Blood Cancer Institute /ID# 279080 | Denver80218 | NCT07095452 | Map |
| CO | Presbyterian - Saint Lukes Medical Center - Health One | Denver80218 | NCT03937635 | Map |
| CO | Mercy Medical Center | Durango81301 | NCT05561387 | Map |
| CO | Southwest Oncology PC | Durango81301 | NCT05561387 | Map |
| CO | The Melanoma and Skin Cancer Institute | Englewood80113 | NCT03937635 | Map |
| CO | Saint Anthony Hospital | Lakewood80228 | NCT03937635 | Map |
| CO | Saint Anthony Hospital | Lakewood80228 | NCT04566328 | Map |
| CO | Saint Anthony Hospital | Lakewood80228 | NCT05561387 | Map |
| CO | Rocky Mountain Cancer Centers-Littleton | Littleton80120 | NCT03937635 | Map |
| CO | Longmont United Hospital | Longmont80501 | NCT03937635 | Map |
| CO | Longmont United Hospital | Longmont80501 | NCT05561387 | Map |
| CO | Saint Mary Corwin Medical Center | Pueblo81004 | NCT03937635 | Map |
| CO | Saint Mary Corwin Medical Center | Pueblo81004 | NCT04566328 | Map |
| CO | Saint Mary Corwin Medical Center | Pueblo81004 | NCT05561387 | Map |
| CO | Rocky Mountain Cancer Centers-Thornton | Thornton80260 | NCT03937635 | Map |
| CO | Saint Anthony North Hospital | Westminster80023 | NCT03937635 | Map |
| CO | Saint Anthony North Hospital | Westminster80023 | NCT04566328 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT05561387 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT06022939 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT05561387 | Map |
| CT | University of Connecticut | Farmington06030 | NCT05552222 | Map |
| CT | Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury06033 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital Care Center at Glastonbury | Glastonbury06033 | NCT05561387 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT05561387 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT06022939 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT05561387 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT06022939 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT05561387 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT06022939 | Map |
| CT | Research Site | New Haven06510 | NCT07391657 | Map |
| CT | Smilow Cancer Center/Yale-New Haven Hospital | New Haven06510 | NCT03937635 | Map |
| CT | Smilow Cancer Center/Yale-New Haven Hospital | New Haven06510 | NCT05561387 | Map |
| CT | Yale New Haven Hospital | New Haven06510 | NCT05552222 | Map |
| CT | Yale University | New Haven06520 | NCT03937635 | Map |
| CT | Yale University | New Haven06520 | NCT05561387 | Map |
| CT | Yale University | New Haven06520 | NCT06022939 | Map |
| CT | Yale University School of Medicine /ID# 272447 | New Haven06510 | NCT06953960 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT03937635 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT05561387 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT06022939 | Map |
| CT | Smilow Cancer Hospital-Orange Care Center | Orange06477 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT05561387 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT06022939 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT05561387 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT05561387 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT06022939 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT05561387 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT03937635 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT05561387 | Map |
| DE | ChristianaCare Helen F Graham Cancer Center and Research Institute | Newark19713 | NCT05552222 | Map |
| DC | Children's National Hospital | Washington D.C.20010 | NCT06358638 | Map |
| DC | Georgetown Lombardi Comprehensive Cancer Center | Washington D.C.20007 | NCT06015724 | Map |
| DC | GSK Investigational Site | Washington D.C.20007 | NCT06679101 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT06022939 | Map |
| FL | Sylvester Comprehensive Cancer Center - Aventura | Aventura33180 | NCT05020236 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Aventura | Aventura33180 | NCT06022939 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT06022939 | Map |
| FL | Sylvester Comprehensive Cancer Center - Coral Springs | Coral Springs33065 | NCT05020236 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Springs | Coral Springs33065 | NCT06022939 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT06022939 | Map |
| FL | University of Miami Hospital and Clinics - Deerfield Beach | Deerfield Beach33442 | NCT05020236 | Map |
| FL | GSK Investigational Site | Englewood34223 | NCT06679101 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT03937635 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT04566328 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT05561387 | Map |
| FL | University of Florida | Gainsville32608 | NCT04972942 | — |
| FL | Memorial Healthcare System | Hollywood33021 | NCT05552222 | Map |
| FL | Sylvester Comprehensive Cancer Center - Hollywood | Hollywood33021 | NCT05020236 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Hollywood | Hollywood33021 | NCT06022939 | Map |
| FL | Baptist MD Anderson Cancer Center | Jacksonville32207 | NCT06615479 | Map |
| FL | Mayo Clinic | Jacksonville32224 | NCT05654506 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT05561387 | Map |
| FL | Jupiter Medical Center | Jupiter33458 | NCT05561387 | Map |
| FL | GSK Investigational Site | Lady Lake32159 | NCT06679101 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT06022939 | Map |
| FL | University of Miami | Miami33136-2107 | NCT04973605 | Map |
| FL | University of Miami | Miami33136 | NCT05896228 | Map |
| FL | University of Miami | Miami33136 | NCT06100237 | Map |
| FL | University of Miami Hospital and Clinics | Miami33136 | NCT05020236 | Map |
| FL | University of Miami Hospital and Clinics, Sylvester Cancer Center | Miami33136 | NCT06615479 | Map |
| FL | University of Miami Miller School of Medicine | Miami33136 | NCT04139304 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT06022939 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami33181 | NCT06022939 | Map |
| FL | AdventHealth Medical Group Blood & Marrow Transplant at Orlando | Orlando32804 | NCT05552222 | Map |
| FL | GSK Investigational Site | Pembroke Pines33024 | NCT06679101 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT06022939 | Map |
| FL | GSK Investigational Site | Saint Augustine32256 | NCT06679101 | Map |
| FL | Moffitt Cancer Center /ID# 272628 | Tampa33612 | NCT06892522 | Map |
| FL | Cleveland Clinic Florida | Weston33331 | NCT05552222 | Map |
| FL | Cleveland Clinic-Weston | Weston33331 | NCT03937635 | Map |
| GA | Phoebe Putney Memorial Hospital | Albany31701 | NCT03937635 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT03937635 | Map |
| GA | Emory University Hospital | Atlanta30322 | NCT06119685 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT03937635 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT06022939 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT03937635 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06022939 | Map |
| GA | Emory University Winship Cancer Center | Atlanta30322-1013 | NCT04973605 | Map |
| GA | Emory Winship Cancer Institute | Atlanta30322 | NCT04068597 | Map |
| GA | GSK Investigational Site | Atlanta30322 | NCT06679101 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30004 | NCT05137054 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30329 | NCT07555938 | Map |
| GA | Winship Cancer Institute of Emory University /ID# 274830 | Atlanta30322 | NCT06892522 | Map |
| GA | Winship Cancer Institute of Emory University /ID# 277667 | Atlanta30322 | NCT07095452 | Map |
| GA | Winship Cancer Institute, Emory University | Atlanta30322 | NCT06615479 | Map |
| GA | Georgia Cancer Center-Augusta University | Augusta30912 | NCT06142396 | Map |
| GA | John B Amos Cancer Center | Columbus31904 | NCT03937635 | Map |
| GA | Emory Johns Creek Hospital | Johns Creek30097 | NCT03937635 | Map |
| GA | City of Hope Cancer Center | Newnan30265 | NCT05552222 | Map |
| GA | Lewis Hall Singletary Oncology Center | Thomasville31792 | NCT03937635 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT03937635 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT04566328 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT03937635 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05561387 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT03937635 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT04566328 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT03937635 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT03937635 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05561387 | Map |
| ID | Idaho Urologic Institute-Meridian | Meridian83642 | NCT03937635 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT03937635 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05561387 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT03937635 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT04566328 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT03937635 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83686 | NCT05561387 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT03937635 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT03937635 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT05561387 | Map |
| IL | OSF Saint Anthony's Health Center | Alton62002 | NCT03937635 | Map |
| IL | OSF Saint Anthony's Health Center | Alton62002 | NCT04566328 | Map |
| IL | Saint Anthony's Health | Alton62002 | NCT05561387 | Map |
| IL | Advocate Outpatient Center - Aurora | Aurora60506 | NCT03937635 | Map |
| IL | Rush - Copley Medical Center | Aurora60504 | NCT05561387 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT03937635 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT06022939 | Map |
| IL | Advocate Good Shepherd Hospital | Barrington60010 | NCT03937635 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT03937635 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT04566328 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT05561387 | Map |
| IL | Saint Joseph Medical Center | Bloomington61701 | NCT05561387 | Map |
| IL | Loyola Center for Health at Burr Ridge | Burr Ridge60527 | NCT05561387 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT03937635 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT04566328 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT05561387 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT03937635 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT04566328 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT05561387 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT03937635 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT04566328 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT05561387 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT03937635 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT04566328 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT05561387 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT03937635 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT04566328 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT05561387 | Map |
| IL | Saint Mary's Hospital | Centralia62801 | NCT05561387 | Map |
| IL | Advocate Illinois Masonic Medical Center | Chicago60657 | NCT03937635 | Map |
| IL | Northwestern | Chicago60611 | NCT05289687 | Map |
| IL | Swedish Covenant Hospital | Chicago60625 | NCT03937635 | Map |
| IL | University of Chicago Medical Center | Chicago60637-1443 | NCT04973605 | Map |
| IL | University of Illinois | Chicago60612 | NCT06022939 | Map |
| IL | University of Illinois at Chicago | Chicago60612 | NCT04139304 | Map |
| IL | University Of Illinois Medical Center | Chicago60612 | NCT05552222 | Map |
| IL | AMG Crystal Lake - Oncology | Crystal Lake60014 | NCT03937635 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT03937635 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05561387 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT06022939 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT03937635 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT04566328 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05561387 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT03937635 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT04566328 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05561387 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT04566328 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT04566328 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT05561387 | Map |
| IL | Advocate Good Samaritan Hospital | Downers Grove60515 | NCT03937635 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT03937635 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05561387 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT06022939 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT03937635 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT04566328 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05561387 | Map |
| IL | Advocate Sherman Hospital | Elgin60123 | NCT03937635 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT03937635 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT04566328 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT05561387 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT03937635 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT03937635 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT04566328 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT05561387 | Map |
| IL | Western Illinois Cancer Treatment Center | Galesburg61401 | NCT05561387 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT04566328 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT03937635 | Map |
| IL | Advocate South Suburban Hospital | Hazel Crest60429 | NCT03937635 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT03937635 | Map |
| IL | Edward Hines Jr VA Hospital | Hines60141 | NCT05561387 | Map |
| IL | Loyola Medicine Homer Glen | Homer Glen60491 | NCT05561387 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT03937635 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT04566328 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT05561387 | Map |
| IL | AMG Libertyville - Oncology | Libertyville60048 | NCT03937635 | Map |
| IL | Condell Memorial Hospital | Libertyville60048 | NCT03937635 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT03937635 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT04566328 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT05561387 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT03937635 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05561387 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT06022939 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT03937635 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT05552222 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT05561387 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT06022939 | Map |
| IL | Marjorie Weinberg Cancer Center at Loyola-Gottlieb | Melrose Park60160 | NCT05561387 | Map |
| IL | Good Samaritan Regional Health Center | Mount Vernon62864 | NCT05561387 | Map |
| IL | SSM Health Good Samaritan | Mount Vernon62864 | NCT03937635 | Map |
| IL | SSM Health Good Samaritan | Mount Vernon62864 | NCT04566328 | Map |
| IL | Carle BroMenn Medical Center | Normal61761 | NCT03937635 | Map |
| IL | Carle Cancer Institute Normal | Normal61761 | NCT03937635 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT03937635 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT04566328 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05561387 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT03937635 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT04566328 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT05561387 | Map |
| IL | Advocate Christ Medical Center | Oak Lawn60453-2699 | NCT03937635 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT03937635 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT04566328 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT05561387 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT03937635 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT03937635 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT04566328 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT05561387 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT03937635 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT04566328 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT05561387 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT03937635 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT04566328 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT05561387 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT03937635 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT04566328 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT05561387 | Map |
| IL | Valley Radiation Oncology | Peru61354 | NCT04566328 | Map |
| IL | Valley Radiation Oncology | Peru61354 | NCT05561387 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT03937635 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT04566328 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT05561387 | Map |
| IL | Memorial Medical Center | Springfield62781 | NCT05561387 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT03937635 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT04566328 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05561387 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT03937635 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT04566328 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05561387 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT03937635 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT04566328 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT03937635 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05561387 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT06022939 | Map |
| IL | The Carle Foundation Hospital | Urbana61801 | NCT03937635 | Map |
| IL | The Carle Foundation Hospital | Urbana61801 | NCT05561387 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT04566328 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT03937635 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT04566328 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT05561387 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT05561387 | Map |
| IN | IU Health North Hospital | Carmel46032 | NCT05561387 | Map |
| IN | Northwest Cancer Center - Main Campus | Crown Point46307 | NCT05561387 | Map |
| IN | Northwest Oncology LLC | Dyer46311 | NCT05561387 | Map |
| IN | Fort Wayne Medical Oncology And Hematology /ID# 278141 | Fort Wayne46804 | NCT07095452 | Map |
| IN | Northwest Cancer Center - Hobart | Hobart46342 | NCT05561387 | Map |
| IN | Saint Mary Medical Center | Hobart46342 | NCT05561387 | Map |
| IN | Community Health Network | Indianapolis46227 | NCT04068597 | Map |
| IN | Indiana University Health Simon Cancer Center | Indianapolis46202 | NCT05137054 | Map |
| IN | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT04566328 | Map |
| IN | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT05561387 | Map |
| IN | Riley Children's Hospital | Indianapolis46202 | NCT04972942 | Map |
| IN | Saint Catherine Hospital | Indianapolis46312 | NCT05561387 | Map |
| IN | The Community Hospital | Munster46321 | NCT05561387 | Map |
| IN | Women's Diagnostic Center - Munster | Munster46321 | NCT05561387 | Map |
| IN | Reid Health | Richmond47374 | NCT03937635 | Map |
| IN | Reid Health | Richmond47374 | NCT05561387 | Map |
| IN | Northwest Cancer Center - Valparaiso | Valparaiso46383 | NCT05561387 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT04566328 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT04566328 | Map |
| IA | Mission Cancer and Blood - Ankeny | Ankeny50023 | NCT05561387 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT03937635 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT04566328 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT06022939 | Map |
| IA | University of Iowa Healthcare Cancer Services Quad Cities | Bettendorf52722 | NCT03937635 | Map |
| IA | University of Iowa Healthcare Cancer Services Quad Cities | Bettendorf52722 | NCT05561387 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT03937635 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT04566328 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT04566328 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT04566328 | Map |
| IA | Physicians' Clinic of Iowa PC | Cedar Rapids52402 | NCT05561387 | Map |
| IA | Medical Oncology and Hematology Associates-West Des Moines | Clive50325 | NCT05561387 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT03937635 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT04566328 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT05561387 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT03937635 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT04566328 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT06022939 | Map |
| IA | Greater Regional Medical Center | Creston50801 | NCT03937635 | Map |
| IA | Greater Regional Medical Center | Creston50801 | NCT04566328 | Map |
| IA | Greater Regional Medical Center | Creston50801 | NCT05561387 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT03937635 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT04566328 | Map |
| IA | Iowa Lutheran Hospital | Des Moines50316 | NCT03937635 | Map |
| IA | Iowa Lutheran Hospital | Des Moines50316 | NCT04566328 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT03937635 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT04566328 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT06022939 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT03937635 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT04566328 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT05561387 | Map |
| IA | Mission Cancer and Blood - Laurel | Des Moines50314 | NCT05561387 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT03937635 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT04566328 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT06022939 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT03937635 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT04566328 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT06022939 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT04566328 | Map |
| IA | UI Healthcare Mission Cancer and Blood - Fort Dodge | Fort Dodge50501 | NCT04566328 | Map |
| IA | University of Iowa | Iowa City52242 | NCT06974786 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT03937635 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05561387 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT04566328 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT03937635 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT04566328 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT06022939 | Map |
| IA | University of Iowa Health Care | Waukee50263 | NCT05552222 | Map |
| IA | Mercy Medical Center-West Lakes | West Des Moines50266 | NCT03937635 | Map |
| IA | Mercy Medical Center-West Lakes | West Des Moines50266 | NCT04566328 | Map |
| IA | Mercy Medical Center-West Lakes | West Des Moines50266 | NCT05561387 | Map |
| IA | Methodist West Hospital | West Des Moines50266-7700 | NCT03937635 | Map |
| IA | Methodist West Hospital | West Des Moines50266-7700 | NCT04566328 | Map |
| KS | Central Care Cancer Center - Garden City | Garden City67846 | NCT03937635 | Map |
| KS | Central Care Cancer Center - Garden City | Garden City67846 | NCT04566328 | Map |
| KS | Central Care Cancer Center - Garden City | Garden City67846 | NCT05561387 | Map |
| KS | Central Care Cancer Center - Great Bend | Great Bend67530 | NCT04566328 | Map |
| KS | Central Care Cancer Center - Great Bend | Great Bend67530 | NCT05561387 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT06022939 | Map |
| KS | Mercy Hospital Pittsburg | Pittsburg66762 | NCT03937635 | Map |
| KS | Mercy Hospital Pittsburg | Pittsburg66762 | NCT04566328 | Map |
| KS | Cotton O'Neil Cancer Center / Stormont Vail Health | Topeka66606 | NCT03937635 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT06022939 | Map |
| KY | Flaget Memorial Hospital | Bardstown40004 | NCT04566328 | Map |
| KY | Flaget Memorial Hospital | Bardstown40004 | NCT05561387 | Map |
| KY | Commonwealth Cancer Center-Corbin | Corbin40701 | NCT04566328 | Map |
| KY | Commonwealth Cancer Center-Corbin | Corbin40701 | NCT05561387 | Map |
| KY | Saint Joseph Hospital | Lexington40504 | NCT03937635 | Map |
| KY | Saint Joseph Hospital | Lexington40504 | NCT05561387 | Map |
| KY | Saint Joseph Hospital East | Lexington40509 | NCT03937635 | Map |
| KY | Saint Joseph Hospital East | Lexington40509 | NCT04566328 | Map |
| KY | Saint Joseph Hospital East | Lexington40509 | NCT05561387 | Map |
| KY | Saint Joseph Radiation Oncology Resource Center | Lexington40504 | NCT03937635 | Map |
| KY | Saint Joseph Radiation Oncology Resource Center | Lexington40504 | NCT04566328 | Map |
| KY | Saint Joseph Radiation Oncology Resource Center | Lexington40504 | NCT05561387 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT03937635 | Map |
| KY | Saint Joseph London | London40741 | NCT04566328 | Map |
| KY | Saint Joseph London | London40741 | NCT05561387 | Map |
| KY | Norton Cancer Institute | Louisville40207 | NCT05552222 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT03937635 | Map |
| KY | University of Louisville-James Graham Brown Cancer Center | Louisville40202 | NCT03899155 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT03937635 | Map |
| KY | Saint Joseph Mount Sterling | Mount Sterling40353 | NCT04566328 | Map |
| KY | Saint Joseph Mount Sterling | Mount Sterling40353 | NCT05561387 | Map |
| LA | LSU Health Baton Rouge-North Clinic | Baton Rouge70805 | NCT03937635 | Map |
| LA | Our Lady of The Lake | Baton Rouge70808 | NCT03937635 | Map |
| LA | Our Lady of the Lake Physician Group | Baton Rouge70808 | NCT03937635 | Map |
| LA | Ochsner Medical Center Jefferson | New Orleans70121 | NCT03937635 | Map |
| LA | Tulane University School of Medicine | New Orleans70112 | NCT03937635 | Map |
| LA | Louisiana State University Health Sciences Shreveport | Shreveport71103 | NCT06615479 | Map |
| LA | LSU Health Sciences Center at Shreveport | Shreveport71103 | NCT03937635 | Map |
| LA | LSUHSC Shreveport Feist-Weiller Cancer Center | Shreveport71103 | NCT05552222 | Map |
| ME | GSK Investigational Site | Portland04074 | NCT06679101 | Map |
| ME | York Hospital | York Village03909 | NCT03937635 | Map |
| MD | Greater Baltimore Medical Center | Baltimore21204 | NCT05561387 | Map |
| MD | Johns Hopkins University | Baltimore21205 | NCT05671757 | Map |
| MD | Johns Hopkins University School of Medicine JHUSOM | Baltimore21231 | NCT05552222 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21231 | NCT04139304 | Map |
| MD | Saint Agnes Hospital | Baltimore21229 | NCT03937635 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore21231 | NCT06398457 | Map |
| MD | University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore21201 | NCT07075510 | Map |
| MD | Center for Cancer and Blood Disorders | Bethesda20817 | NCT05552222 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT05907759 | Map |
| MD | The Center for Cancer and Blood Disorders (CCBD) | Bethesda20817 | NCT04068597 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT06022939 | Map |
| MA | Boston Children's Hospital | Boston02115 | NCT04972942 | Map |
| MA | Boston Medical Center | Boston02118 | NCT05451771 | Map |
| MA | Boston Medical Center | Boston02118 | NCT06022939 | Map |
| MA | Boston Medical Center | Boston02118 | NCT06615479 | Map |
| MA | Brigham and Women's Hospital | Boston02130 | NCT06483139 | Map |
| MA | Dana Farber / Harvard Cancer Center | Boston02215 | NCT07393282 | Map |
| MA | Dana Farber/Harvard Cancer Center | Boston02215 | NCT05137054 | Map |
| MA | Dana_Farber Cancer Institute (DFCI) | Boston02215 | NCT03899155 | Map |
| MA | Dana-Farber Cancer Institute /ID# 271846 | Boston02215 | NCT06953960 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT03937635 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT04566328 | Map |
| MA | Tufts Medical Center Cancer Center Stoneham | Stoneham02180 | NCT04566328 | Map |
| MA | GSK Investigational Site | Worcester01655 | NCT06679101 | Map |
| MI | MyMichigan Medical Center Gratiot | Alma48801 | NCT03937635 | Map |
| MI | MyMichigan Medical Center Gratiot | Alma48801 | NCT04566328 | Map |
| MI | MyMichigan Medical Center Alpena | Alpena49707 | NCT04566328 | Map |
| MI | GSK Investigational Site | Ann Arbor48103 | NCT06679101 | Map |
| MI | Saint Joseph Mercy Hospital | Ann Arbor48106 | NCT05561387 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT03937635 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT04566328 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT05552222 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT05671757 | Map |
| MI | University of Michigan Health System - Ann Arbor /ID# 271536 | Ann Arbor48109 | NCT06953960 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT03937635 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT06022939 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT03937635 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT05561387 | Map |
| MI | Saint Joseph Mercy Brighton | Brighton48114 | NCT05561387 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT03937635 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT04566328 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05561387 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT03937635 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT04566328 | Map |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT03937635 | — |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT06022939 | — |
| MI | Saint Joseph Mercy Canton | Canton48188 | NCT05561387 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT03937635 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT04566328 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05561387 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT03937635 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT04566328 | Map |
| MI | Caro Cancer Center | Caro48723 | NCT05561387 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT03937635 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT04566328 | Map |
| MI | Saint Joseph Mercy Chelsea | Chelsea48118 | NCT05561387 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT03937635 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT04566328 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05561387 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT04566328 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT05561387 | Map |
| MI | Newland Medical Associates-Clarkston | Clarkston48346 | NCT04566328 | Map |
| MI | Newland Medical Associates-Clarkston | Clarkston48346 | NCT05561387 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT03937635 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT06022939 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT03937635 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT06022939 | Map |
| MI | Ascension Saint John Hospital | Detroit48236 | NCT05561387 | Map |
| MI | GSK Investigational Site | Detroit48201 | NCT06679101 | Map |
| MI | Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion | Detroit48202 | NCT05552222 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT03937635 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT04566328 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT03937635 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT06022939 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT05137054 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT06107738 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT06022939 | Map |
| MI | Great Lakes Cancer Management Specialists-Doctors Park | East China48054 | NCT05561387 | — |
| MI | Henry Ford River District Hospital | East China Township48054 | NCT04566328 | — |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT04566328 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT06022939 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT04566328 | Map |
| MI | Genesee Cancer and Blood Disease Treatment Center | Flint48503 | NCT05561387 | Map |
| MI | Genesee Hematology Oncology PC | Flint48503 | NCT04566328 | Map |
| MI | Genesee Hematology Oncology PC | Flint48503 | NCT05561387 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT03937635 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT04566328 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05561387 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT03937635 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT04566328 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05561387 | Map |
| MI | MyMichigan Medical Center Gladwin | Gladwin48624 | NCT04566328 | Map |
| MI | Cancer And Hematology Centers of Western Michigan PC | Grand Rapids49503 | NCT05552222 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT03937635 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT03937635 | Map |
| MI | Helen DeVos Children's Hospital | Grand Rapids49503 | NCT04972942 | Map |
| MI | Helen DeVos Children's Hospital at Spectrum Health | Grand Rapids49503 | NCT05561387 | Map |
| MI | Spectrum Health at Butterworth Campus | Grand Rapids49503 | NCT05561387 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT03937635 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT05561387 | Map |
| MI | Academic Hematology Oncology Specialists | Grosse Pointe Woods48236 | NCT05561387 | Map |
| MI | Great Lakes Cancer Management Specialists-Van Elslander Cancer Center | Grosse Pointe Woods48236 | NCT05561387 | Map |
| MI | Henry Ford Saint John Hospital - Academic | Grosse Pointe Woods48236 | NCT04566328 | Map |
| MI | Henry Ford Saint John Hospital - Breast | Grosse Pointe Woods48236 | NCT04566328 | Map |
| MI | Henry Ford Saint John Hospital - Van Elslander | Grosse Pointe Woods48236 | NCT03937635 | Map |
| MI | Henry Ford Saint John Hospital - Van Elslander | Grosse Pointe Woods48236 | NCT04566328 | Map |
| MI | Allegiance Health | Jackson49201 | NCT03937635 | Map |
| MI | Allegiance Health | Jackson49201 | NCT06022939 | Map |
| MI | Ascension Borgess Cancer Center | Kalamazoo49009 | NCT05561387 | Map |
| MI | Beacon Kalamazoo | Kalamazoo49048 | NCT03937635 | Map |
| MI | Borgess Medical Center | Kalamazoo49048 | NCT05561387 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT03937635 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT05561387 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT03937635 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT05561387 | Map |
| MI | Karmanos Cancer Institute at McLaren Greater Lansing | Lansing48910 | NCT06022939 | Map |
| MI | KCI at McLaren Greater Lansing | Lansing48910 | NCT06107738 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT03937635 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT04566328 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT05561387 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT03937635 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT04566328 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05561387 | Map |
| MI | Great Lakes Cancer Management Specialists-Macomb Medical Campus | Macomb48044 | NCT05561387 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT03937635 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT04566328 | Map |
| MI | Henry Ford Warren Hospital - Breast Macomb | Macomb48044 | NCT04566328 | Map |
| MI | Saint Mary's Oncology/Hematology Associates of Marlette | Marlette48453 | NCT05561387 | Map |
| MI | MyMichigan Medical Center Midland | Midland48670 | NCT03937635 | Map |
| MI | MyMichigan Medical Center Midland | Midland48670 | NCT04566328 | Map |
| MI | MyMichigan Medical Center Mount Pleasant | Mount Pleasant48858 | NCT04566328 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT03937635 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT05561387 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT03937635 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT05561387 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT03937635 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT05561387 | Map |
| MI | Henry Ford Health Providence Novi Hospital | Novi48374 | NCT03937635 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT03937635 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT06022939 | Map |
| MI | Henry Ford Providence Novi Hospital | Novi48374 | NCT05552222 | Map |
| MI | 21st Century Oncology-Pontiac | Pontiac48341 | NCT05561387 | Map |
| MI | Hope Cancer Center | Pontiac48341 | NCT04566328 | Map |
| MI | Hope Cancer Center | Pontiac48341 | NCT05561387 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT03937635 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT04566328 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT04566328 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT05561387 | Map |
| MI | Saint Joseph Mercy Oakland | Pontiac48341 | NCT05561387 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT03937635 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT04566328 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT03937635 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT05561387 | Map |
| MI | Ascension Saint Mary's Hospital | Saginaw48601 | NCT05561387 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT03937635 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT04566328 | Map |
| MI | Oncology Hematology Associates of Saginaw Valley PC | Saginaw48604 | NCT05561387 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT03937635 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT05561387 | Map |
| MI | Corewell Health Lakeland Hospitals - Saint Joseph Hospital | Saint Joseph49085 | NCT03937635 | Map |
| MI | Lakeland Medical Center Saint Joseph | Saint Joseph49085 | NCT05561387 | Map |
| MI | Henry Ford Health Providence Southfield Hospital | Southfield48075 | NCT03937635 | Map |
| MI | Henry Ford Providence Southfield CK Potluri Cancer Center | Southfield48075 | NCT05552222 | Map |
| MI | Bhadresh Nayak MD PC-Sterling Heights | Sterling Heights48312 | NCT05561387 | Map |
| MI | Ascension Saint Joseph Hospital | Tawas City48764 | NCT05561387 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT03937635 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT04566328 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT03937635 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT05561387 | Map |
| MI | Advanced Breast Care Center PLLC | Warren48088 | NCT05561387 | Map |
| MI | Great Lakes Cancer Management Specialists-Macomb Professional Building | Warren48093 | NCT05561387 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT03937635 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT04566328 | Map |
| MI | Henry Ford Madison Heights Hospital - Breast | Warren48093 | NCT04566328 | Map |
| MI | Henry Ford Warren Hospital - GLCMS | Warren48093 | NCT04566328 | Map |
| MI | Macomb Hematology Oncology PC | Warren48093 | NCT05561387 | Map |
| MI | Michigan Breast Specialists-Warren | Warren48093 | NCT05561387 | Map |
| MI | Saint John Macomb-Oakland Hospital | Warren48093 | NCT05561387 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT03937635 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT06022939 | Map |
| MI | Saint Mary's Oncology/Hematology Associates of West Branch | West Branch48661 | NCT05561387 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT03937635 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT06022939 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT03937635 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT05561387 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT04566328 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT05561387 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT03937635 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT04566328 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05561387 | Map |
| MN | Riverwood Healthcare Center | Aitkin56431 | NCT05561387 | Map |
| MN | Essentia Health - Baxter Clinic | Baxter56425 | NCT05561387 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT05561387 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT03937635 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT05561387 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT03937635 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT04566328 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT05561387 | Map |
| MN | Cambridge Medical Center | Cambridge55008 | NCT04566328 | Map |
| MN | Cambridge Medical Center | Cambridge55008 | NCT05561387 | Map |
| MN | Minnesota Oncology Hematology PA-Chaska | Chaska55318 | NCT03937635 | Map |
| MN | Minnesota Oncology Hematology PA-Chaska | Chaska55318 | NCT04566328 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT03937635 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT04566328 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05561387 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT06022939 | Map |
| MN | Minnesota Oncology - Coon Rapids | Coon Rapids55433 | NCT03937635 | Map |
| MN | Minnesota Oncology - Coon Rapids | Coon Rapids55433 | NCT04566328 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT03937635 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05561387 | Map |
| MN | Essentia Health Saint Mary's - Detroit Lakes Clinic | Detroit Lakes56501 | NCT03937635 | Map |
| MN | Essentia Health Saint Mary's - Detroit Lakes Clinic | Detroit Lakes56501 | NCT05561387 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT03937635 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05561387 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT03937635 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT05561387 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT03937635 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT05561387 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT03937635 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT04566328 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05561387 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT06022939 | Map |
| MN | Minnesota Oncology - Edina | Edina55435 | NCT03937635 | Map |
| MN | Minnesota Oncology - Edina | Edina55435 | NCT04566328 | Map |
| MN | Essentia Health - Ely Clinic | Ely55731 | NCT05561387 | Map |
| MN | Essentia Health - Fosston | Fosston56542 | NCT03937635 | Map |
| MN | Essentia Health - Fosston | Fosston56542 | NCT05561387 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT03937635 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05561387 | Map |
| MN | Essentia Health - International Falls Clinic | International Falls56649 | NCT05561387 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT03937635 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT04566328 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT05561387 | Map |
| MN | Minnesota Oncology - Maple Grove | Maple Grove55369 | NCT03937635 | Map |
| MN | Minnesota Oncology - Maple Grove | Maple Grove55369 | NCT04566328 | Map |
| MN | Minnesota Oncology Hematology PA-Maplewood | Maplewood55109 | NCT03937635 | Map |
| MN | Minnesota Oncology Hematology PA-Maplewood | Maplewood55109 | NCT04566328 | Map |
| MN | Minnesota Oncology Hematology PA-Maplewood | Maplewood55109 | NCT05561387 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT03937635 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT04566328 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT05561387 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT03937635 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT04566328 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05561387 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT06022939 | Map |
| MN | Health Partners Inc | Minneapolis55454 | NCT03937635 | Map |
| MN | Health Partners Inc | Minneapolis55454 | NCT05561387 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT03937635 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT04566328 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT05561387 | Map |
| MN | Minnesota Oncology - Minneapolis Clinic /ID# 278720 | Minneapolis55404 | NCT07095452 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT06119685 | Map |
| MN | Monticello Cancer Center | Monticello55362 | NCT03937635 | Map |
| MN | Monticello Cancer Center | Monticello55362 | NCT04566328 | Map |
| MN | Monticello Cancer Center | Monticello55362 | NCT05561387 | Map |
| MN | Essentia Health - Moose Lake Clinic | Moose Lake55767 | NCT05561387 | Map |
| MN | New Ulm Medical Center | New Ulm56073 | NCT04566328 | Map |
| MN | New Ulm Medical Center | New Ulm56073 | NCT05561387 | Map |
| MN | Essentia Health - Park Rapids | Park Rapids56470 | NCT03937635 | Map |
| MN | Essentia Health - Park Rapids | Park Rapids56470 | NCT05561387 | Map |
| MN | Fairview Northland Medical Center | Princeton55371 | NCT04566328 | Map |
| MN | Fairview Northland Medical Center | Princeton55371 | NCT05561387 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT03937635 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT04566328 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT05561387 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT05137054 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT05654506 | Map |
| MN | Mayo Clinic Hospital Rochester /ID# 277886 | Rochester55905 | NCT07095452 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT04566328 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05561387 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05898646 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06022939 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06042725 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06785415 | Map |
| MN | Mayo Clinic Rochester | Rochester55905 | NCT05451771 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT03937635 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT04566328 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05561387 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT06022939 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT03937635 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT04566328 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05561387 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT06022939 | Map |
| MN | United Hospital | Saint Paul55102 | NCT03937635 | Map |
| MN | United Hospital | Saint Paul55102 | NCT04566328 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05561387 | Map |
| MN | United Hospital | Saint Paul55102 | NCT06022939 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT03937635 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05561387 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT03937635 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT04566328 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT05561387 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT03937635 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT04566328 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT05561387 | Map |
| MN | Sanford Thief River Falls Medical Center | Thief River Falls56701 | NCT05561387 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT03937635 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05561387 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT03937635 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT04566328 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT05561387 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT03937635 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT04566328 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT05561387 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT03937635 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT04566328 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT05561387 | Map |
| MN | Sanford Cancer Center Worthington | Worthington56187 | NCT05561387 | Map |
| MN | Fairview Lakes Medical Center | Wyoming55092 | NCT04566328 | Map |
| MN | Fairview Lakes Medical Center | Wyoming55092 | NCT05561387 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT06022939 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT06022939 | Map |
| MO | Mercy Oncology and Hematology - Clayton-Clarkson | Ballwin63011 | NCT04566328 | Map |
| MO | Saint Louis Cancer and Breast Institute-Ballwin | Ballwin63011 | NCT05561387 | Map |
| MO | Central Care Cancer Center - Bolivar | Bolivar65613 | NCT03937635 | Map |
| MO | Central Care Cancer Center - Bolivar | Bolivar65613 | NCT04566328 | Map |
| MO | Central Care Cancer Center - Bolivar | Bolivar65613 | NCT05561387 | Map |
| MO | Cox Cancer Center Branson | Branson65616 | NCT04566328 | Map |
| MO | Cox Cancer Center Branson | Branson65616 | NCT05561387 | Map |
| MO | Mercy Cancer Center - Cape Girardeau | Cape Girardeau63703 | NCT03937635 | Map |
| MO | Mercy Cancer Center - Cape Girardeau | Cape Girardeau63703 | NCT04566328 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT03937635 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT04566328 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05561387 | Map |
| MO | Southeast Cancer Center | Cape Girardeau63703 | NCT05561387 | Map |
| MO | Saint Luke's Hospital | Chesterfield63017 | NCT03937635 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT03937635 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT06022939 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT03937635 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT06022939 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT03937635 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT04566328 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT05561387 | Map |
| MO | Capital Region Southwest Campus | Jefferson City65109 | NCT05561387 | Map |
| MO | Freeman Health System | Joplin64804 | NCT03937635 | Map |
| MO | Freeman Health System | Joplin64804 | NCT04566328 | Map |
| MO | Freeman Health System | Joplin64804 | NCT05561387 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT03937635 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT04566328 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT05561387 | Map |
| MO | MidAmerica Cancer Care | Kansas City64132 | NCT05552222 | Map |
| MO | Research Medical Center | Kansas City64132 | NCT05561387 | Map |
| MO | Lake Regional Hospital | Osage Beach65065 | NCT03937635 | Map |
| MO | Lake Regional Hospital | Osage Beach65065 | NCT04566328 | Map |
| MO | Lake Regional Hospital | Osage Beach65065 | NCT05561387 | Map |
| MO | Delbert Day Cancer Institute at PCRMC | Rolla65401 | NCT05561387 | Map |
| MO | Mercy Clinic-Rolla-Cancer and Hematology | Rolla65401 | NCT03937635 | Map |
| MO | Mercy Clinic-Rolla-Cancer and Hematology | Rolla65401 | NCT04566328 | Map |
| MO | Mercy Clinic-Rolla-Cancer and Hematology | Rolla65401 | NCT05561387 | Map |
| MO | Phelps Health Delbert Day Cancer Institute | Rolla65401 | NCT03937635 | Map |
| MO | Phelps Health Delbert Day Cancer Institute | Rolla65401 | NCT04566328 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT03937635 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT04566328 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT05561387 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT03937635 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT04566328 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT05561387 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT03937635 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT04566328 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT05561387 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT03937635 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT04566328 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT05561387 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT03937635 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT04566328 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT05561387 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT03937635 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT04566328 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT05561387 | Map |
| MO | Mercy Infusion Center - Chippewa | St Louis63109 | NCT04566328 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT03937635 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT04566328 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT05561387 | Map |
| MO | Saint Louis Cancer and Breast Institute-South City | St Louis63109 | NCT05561387 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT03937635 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT06022939 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT03937635 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT06022939 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT03937635 | Map |
| MO | Washington University School of Medicine | St Louis63110-1010 | NCT04973605 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06022939 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT03937635 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT04566328 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT05561387 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT03937635 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT04566328 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT05561387 | Map |
| MO | Mercy Hospital Washington | Washington63090 | NCT04566328 | Map |
| MO | Mercy Hospital Washington | Washington63090 | NCT05561387 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT03937635 | Map |
| MT | GSK Investigational Site | Billings59102 | NCT06679101 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT03937635 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT03937635 | Map |
| MT | Great Falls Clinic | Great Falls59405 | NCT03937635 | Map |
| MT | Hi-Line Sletten Cancer Center | Havre59501 | NCT03937635 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT03937635 | Map |
| MT | Community Medical Center | Missoula59804 | NCT03937635 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT03937635 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT05561387 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT06022939 | Map |
| NE | CHI Health Saint Francis | Grand Island68803 | NCT04566328 | Map |
| NE | CHI Health Good Samaritan | Kearney68847 | NCT03937635 | Map |
| NE | CHI Health Good Samaritan | Kearney68847 | NCT04566328 | Map |
| NE | CHI Health Good Samaritan | Kearney68847 | NCT05561387 | Map |
| NE | Alegent Health Bergan Mercy Medical Center | Omaha68124 | NCT03937635 | Map |
| NE | Alegent Health Bergan Mercy Medical Center | Omaha68124 | NCT04566328 | Map |
| NE | Alegent Health Bergan Mercy Medical Center | Omaha68124 | NCT05561387 | Map |
| NE | Alegent Health Immanuel Medical Center | Omaha68122 | NCT04566328 | Map |
| NE | Alegent Health Immanuel Medical Center | Omaha68122 | NCT05561387 | Map |
| NE | Alegent Health Lakeside Hospital | Omaha68130 | NCT04566328 | Map |
| NE | Alegent Health Lakeside Hospital | Omaha68130 | NCT05561387 | Map |
| NE | Creighton University Medical Center | Omaha68131 | NCT03937635 | Map |
| NE | Creighton University Medical Center | Omaha68131 | NCT05561387 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT04068597 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT05552222 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT06022939 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT03937635 | Map |
| NE | University of Nebraska Medical Center | Omaha68198-6846 | NCT04068597 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05552222 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06022939 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Henderson | Henderson89052 | NCT03937635 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT03937635 | Map |
| NV | Comprehensive Cancer Centers of Nevada | Las Vegas89148 | NCT03937635 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Central Valley | Las Vegas89169 | NCT03937635 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Northwest | Las Vegas89128 | NCT03937635 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Town Center | Las Vegas89144 | NCT03937635 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Summerlin | Las Vegas89144 | NCT03937635 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT03937635 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT03937635 | Map |
| NV | OptumCare Cancer Care at MountainView | Las Vegas89128 | NCT03937635 | Map |
| NV | Radiation Oncology Centers of Nevada Central | Las Vegas89106 | NCT03937635 | Map |
| NV | Radiation Oncology Centers of Nevada Southeast | Las Vegas89119 | NCT03937635 | Map |
| NV | Summerlin Hospital Medical Center | Las Vegas89144 | NCT03937635 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT03937635 | Map |
| NH | Exeter Hospital | Exeter03833 | NCT05561387 | Map |
| NH | Dartmouth Hitchcock Medical Center | Lebanon03756 | NCT05552222 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06083922 | Map |
| NJ | MSK Basking Ridge | Basking Ridge07920 | NCT05623020 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT03937635 | Map |
| NJ | Astera Cancer Care | East Brunswick08816 | NCT05552222 | Map |
| NJ | GSK Investigational Site | Hackensack07601 | NCT06679101 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601-1915 | NCT04973605 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601 | NCT06015724 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT06022939 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06083922 | Map |
| NJ | MSK Monmouth | Middletown07748 | NCT05623020 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT06022939 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06083922 | Map |
| NJ | MSK Bergen | Montvale07645 | NCT05623020 | Map |
| NJ | Morristown Medical Center | Morristown07960 | NCT03937635 | Map |
| NJ | Overlook Hospital | Summit07902 | NCT03937635 | Map |
| NJ | MD Anderson Cancer Center at Cooper-Voorhees | Voorhees Township08043 | NCT03937635 | Map |
| NM | Lovelace Medical Center-Saint Joseph Square | Albuquerque87102 | NCT05561387 | Map |
| NM | Presbyterian Kaseman Hospital | Albuquerque87110 | NCT05561387 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87102 | NCT05561387 | Map |
| NM | Presbyterian Rust Medical Center/Jorgensen Cancer Center | Rio Rancho87124 | NCT05561387 | Map |
| NM | Christus St. Vincent Regional Cancer Center | Santa Fe87505 | NCT05552222 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT03899155 | Map |
| NY | Roswell Park Comprehensive Cancer Center | Buffalo14263 | NCT06622005 | Map |
| NY | Hematology Oncology Associates of CNY at Camillus | Camillus13031 | NCT03937635 | Map |
| NY | Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) | Commack11725 | NCT06083922 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT06022939 | Map |
| NY | MSK Commack | Commack11725 | NCT05623020 | Map |
| NY | Hematology Oncology Associates of Central New York-East Syracuse | East Syracuse13057 | NCT03937635 | Map |
| NY | Hematology-Oncology Associates of CNY | East Syracuse13057 | NCT05552222 | Map |
| NY | Northwell Health | Great Neck11021 | NCT05671757 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT06022939 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT06083922 | Map |
| NY | MSK Westchester | Harrison10604 | NCT05623020 | Map |
| NY | Northwell Health Cancer Institute | Lake Success11042 | NCT05552222 | Map |
| NY | NYU Langone Hematology Oncology Associates-Mineola | Mineola11501 | NCT03899155 | Map |
| NY | NYU Langone Hospital Long Island | Mineola11500 | NCT05552222 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT07110844 | Map |
| NY | GSK Investigational Site | New York10065 | NCT06679101 | Map |
| NY | Hospital for Special Surgery | New York10021 | NCT05671757 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT06827860 | Map |
| NY | Icahn School of Medicine at Mount Sinai /ID# 277844 | New York10029 | NCT07095452 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10021 | NCT04139304 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05552222 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06022939 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10021 | NCT07222761 | Map |
| NY | Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). | New York10021 | NCT05020236 | Map |
| NY | Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). | New York10021 | NCT05623020 | Map |
| NY | Memorial Sloan Kettering Cancer Center - Main Campus | New York10065 | NCT05020236 | Map |
| NY | Memorial Sloan Kettering Cancer Center - Main Campus | New York10065 | NCT05623020 | Map |
| NY | Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214 | New York10065 | NCT06953960 | Map |
| NY | Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946 | New York10065 | NCT07095452 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT06083922 | Map |
| NY | Memorial Sloan Kettering Cancer Center Mskcc | New York10065-6800 | NCT04973605 | Map |
| NY | Memorial Sloan Kettering Cancer Center-Main Campus | New York10065 | NCT05623020 | Map |
| NY | Mount Sinai Chelsea | New York10011 | NCT03937635 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT03937635 | Map |
| NY | New York Presbyterian Hospital Columbia University Medical Center | New York10032 | NCT05137054 | Map |
| NY | New York Presbyterian Hospital/Columbia University Irving Medical Center | New York10032 | NCT05451771 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT03937635 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT05561387 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT06022939 | Map |
| NY | NYU Langone | New York10016 | NCT05671757 | Map |
| NY | Perlmutter Cancer Center at NYU Langone Health | New York10016 | NCT05552222 | Map |
| NY | Weill Cornell | New York10021 | NCT05671757 | Map |
| NY | Weill Cornell Medical College | New York10065 | NCT05552222 | Map |
| NY | Weill Cornell Medical College | New York10065 | NCT06615479 | Map |
| NY | Weill Cornell Medical College /ID# 272517 | New York10065 | NCT06892522 | Map |
| NY | Weill Cornell Medical College Newyork Presbyterian Hospital | New York10065-4870 | NCT04973605 | Map |
| NY | Weill Cornell Medicine Myeloma Center /ID# 278216 | New York10065 | NCT07095452 | Map |
| NY | Weill Cornell Medicine/New York Presbyterian Hospital | New York10021 | NCT05137054 | Map |
| NY | University of Rochester | Rochester14642 | NCT04566328 | Map |
| NY | University of Rochester | Rochester14642 | NCT05561387 | Map |
| NY | University of Rochester | Rochester14642 | NCT06022939 | Map |
| NY | GSK Investigational Site | Stony Brook11790 | NCT06679101 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT06083922 | Map |
| NY | MSK Nassau | Uniondale11553 | NCT05623020 | Map |
| NY | New York Medical College | Vallhala10595 | NCT04972942 | — |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT03937635 | Map |
| NC | University North Carolina at Chapel Hill | Chapel Hill27599 | NCT05654506 | Map |
| NC | University of North Carolina | Chapel Hill27599 | NCT06974786 | Map |
| NC | University of North Carolina - Chapel Hill | Chapel Hill27514 | NCT04139304 | Map |
| NC | University of North Carolina (Data Collection Only) | Chapel Hill27514 | NCT06083922 | Map |
| NC | University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT05137054 | Map |
| NC | University of North Carolina at Chapel Hill /ID# 272454 | Chapel Hill27514 | NCT06953960 | Map |
| NC | University of North Carolina at Chapel Hill /ID# 274667 | Chapel Hill27514 | NCT06892522 | Map |
| NC | University of North Carolina at Chapel Hill /ID# 277708 | Chapel Hill27514 | NCT07095452 | Map |
| NC | Atrium Health Levine Cancer Institute /ID# 271510 | Charlotte28204 | NCT06953960 | Map |
| NC | Atrium Health Levine Cancer Institute /ID# 276193 | Charlotte28204-2990 | NCT06892522 | Map |
| NC | GSK Investigational Site | Charlotte28204 | NCT06679101 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT05552222 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT06413498 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT06615479 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT06615479 | Map |
| NC | Novant Health | Charlotte28204 | NCT05552222 | Map |
| NC | Novant Health Presbyterian Medical Center | Charlotte28204 | NCT06022939 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT04566328 | Map |
| NC | Duke University | Durham27710 | NCT05671757 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06022939 | Map |
| NC | Durham VAMC | Durham27705 | NCT05552222 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT04566328 | Map |
| NC | East Carolina University | Greenville27834 | NCT03937635 | Map |
| NC | University of North Carolina-Hillsborough Campus | Hillsborough27278 | NCT03937635 | Map |
| NC | Novant Health Cancer Institute - Huntersville | Huntersville28078 | NCT06022939 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT04566328 | Map |
| NC | ECU Health Oncology Kenansville | Kenansville28349 | NCT03937635 | Map |
| NC | ECU Health Oncology Kinston | Kinston28501 | NCT03937635 | Map |
| NC | Novant Health Cancer Institute - Mooresville | Mooresville28117 | NCT06022939 | Map |
| NC | ECU Health Oncology Richlands | Richlands28574 | NCT03937635 | Map |
| NC | Marion L Shepard Cancer Center - ECU Health Beaufort Hospital | Washington27889 | NCT03937635 | Map |
| NC | Novant Health Zimmer Cancer Institute | Wilmington28401 | NCT05552222 | Map |
| NC | Atrium Health Wake Forest Baptist | Winston-Salem27157 | NCT06119685 | Map |
| NC | Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem27157 | NCT05552222 | Map |
| NC | Atrium Health Wake Forest Baptist Medical Center /ID# 274847 | Winston-Salem27157 | NCT06892522 | Map |
| NC | GSK Investigational Site | Winston-Salem27103 | NCT06679101 | Map |
| NC | Novant Health Forsyth Medical Center | Winston-Salem27103 | NCT05552222 | Map |
| NC | Novant Health Forsyth Medical Center | Winston-Salem27103 | NCT06022939 | Map |
| NC | Wake Forest Baptist Health /ID# 271294 | Winston-Salem27103 | NCT06953960 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05137054 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05561387 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT03937635 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT05561387 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05561387 | Map |
| ND | Sanford Medical Center Fargo | Fargo58104 | NCT05561387 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05561387 | Map |
| ND | Sanford South University Medical Center | Fargo58103 | NCT05561387 | Map |
| ND | Southpointe-Sanford Medical Center Fargo | Fargo58103 | NCT05561387 | Map |
| ND | Essentia Health - Jamestown Clinic | Jamestown58401 | NCT03937635 | Map |
| ND | Essentia Health - Jamestown Clinic | Jamestown58401 | NCT05561387 | Map |
| OH | OhioHealth O'Bleness Hospital | Athens45701 | NCT04566328 | Map |
| OH | Indu and Raj Soin Medical Center | Beavercreek45431 | NCT03937635 | Map |
| OH | Indu and Raj Soin Medical Center | Beavercreek45431 | NCT05561387 | Map |
| OH | Saint Elizabeth Boardman Hospital | Boardman44512 | NCT03937635 | Map |
| OH | Saint Elizabeth Boardman Hospital | Boardman44512 | NCT05561387 | Map |
| OH | Dayton Physicians LLC-Miami Valley South | Centerville45459 | NCT05561387 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT03937635 | Map |
| OH | Geauga Hospital | Chardon44024 | NCT03937635 | Map |
| OH | Adena Regional Medical Center | Chillicothe45601 | NCT03937635 | Map |
| OH | Bethesda North Hospital | Cincinnati45242 | NCT03937635 | Map |
| OH | Bethesda North Hospital | Cincinnati45242 | NCT04566328 | Map |
| OH | Bethesda North Hospital | Cincinnati45242 | NCT05561387 | Map |
| OH | Good Samaritan Hospital - Cincinnati | Cincinnati45220 | NCT03937635 | Map |
| OH | Good Samaritan Hospital - Cincinnati | Cincinnati45220 | NCT04566328 | Map |
| OH | Good Samaritan Hospital - Cincinnati | Cincinnati45220 | NCT05561387 | Map |
| OH | Oncology Hematology Care | Cincinnati45242 | NCT03899155 | Map |
| OH | Oncology Hematology Care | Cincinnati45236 | NCT05552222 | Map |
| OH | Oncology Hematology Care - Kenwood /ID# 272918 | Cincinnati45236 | NCT06892522 | Map |
| OH | Oncology Hematology Care Inc-Kenwood | Cincinnati45236 | NCT05561387 | Map |
| OH | The Christ Hospital Cancer Center | Cincinnati45219 | NCT05552222 | Map |
| OH | TriHealth Cancer Institute-Anderson | Cincinnati45255 | NCT04566328 | Map |
| OH | TriHealth Cancer Institute-Anderson | Cincinnati45255 | NCT05561387 | Map |
| OH | TriHealth Cancer Institute-Westside | Cincinnati45247 | NCT04566328 | Map |
| OH | TriHealth Cancer Institute-Westside | Cincinnati45247 | NCT05561387 | Map |
| OH | University of Cincinnati | Cincinnati45267 | NCT05552222 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT03937635 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT06022939 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT06615479 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT03937635 | Map |
| OH | Cleveland Clinic Main Campus | Cleveland44195 | NCT05552222 | Map |
| OH | MetroHealth Medical Center | Cleveland44109 | NCT03937635 | Map |
| OH | MetroHealth Medical Center | Cleveland44109 | NCT04566328 | Map |
| OH | University Hospitals Cleveland | Cleveland44106 | NCT06119685 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT05552222 | Map |
| OH | Columbus Oncology and Hematology Associates Inc | Columbus43214 | NCT04566328 | Map |
| OH | Doctors Hospital | Columbus43228 | NCT03937635 | Map |
| OH | Doctors Hospital | Columbus43228 | NCT04566328 | Map |
| OH | Grant Medical Center | Columbus43215 | NCT03937635 | Map |
| OH | Grant Medical Center | Columbus43215 | NCT04566328 | Map |
| OH | GSK Investigational Site | Columbus43214 | NCT06679101 | Map |
| OH | Mount Carmel East Hospital | Columbus43213 | NCT03937635 | Map |
| OH | Mount Carmel Health Center West | Columbus43222 | NCT03937635 | Map |
| OH | OhioHealth | Columbus43214 | NCT05552222 | Map |
| OH | OhioHealth | Columbus43214 | NCT07222761 | Map |
| OH | Riverside Methodist Hospital | Columbus43214 | NCT03937635 | Map |
| OH | Riverside Methodist Hospital | Columbus43214 | NCT04566328 | Map |
| OH | Riverside Methodist Hospital | Columbus43214 | NCT06022939 | Map |
| OH | The James Cancer Hospital and Solove Research Institute At Ohio State University | Columbus43210-1240 | NCT04973605 | Map |
| OH | The Mark H Zangmeister Center | Columbus43219 | NCT03937635 | Map |
| OH | The Ohio State University | Columbus43210 | NCT04139304 | Map |
| OH | The Ohio State University James Cancer Hospital | Columbus43210 | NCT05137054 | Map |
| OH | The Ohio State University- James Cancer Hospital | Columbus43210 | NCT05552222 | Map |
| OH | The Ohio State University- The James Cancer Hospital and Solove Research Institute | Columbus43210 | NCT06974786 | Map |
| OH | The Ohio University | Columbus43210 | NCT03899155 | Map |
| OH | Dayton Physician LLC - Englewood | Dayton45415 | NCT03937635 | Map |
| OH | Dayton Physician LLC-Miami Valley Hospital North | Dayton45415 | NCT05561387 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT03937635 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT03937635 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT03937635 | Map |
| OH | Delaware Health Center-Grady Cancer Center | Delaware43015 | NCT03937635 | Map |
| OH | Delaware Health Center-Grady Cancer Center | Delaware43015 | NCT04566328 | Map |
| OH | Grady Memorial Hospital | Delaware43015 | NCT03937635 | Map |
| OH | Grady Memorial Hospital | Delaware43015 | NCT04566328 | Map |
| OH | Columbus Oncology and Hematology Associates | Dublin43016 | NCT04566328 | Map |
| OH | Dublin Methodist Hospital | Dublin43016 | NCT03937635 | Map |
| OH | Dublin Methodist Hospital | Dublin43016 | NCT04566328 | Map |
| OH | Armes Family Cancer Center | Findlay45840 | NCT03937635 | Map |
| OH | Armes Family Cancer Center | Findlay45840 | NCT05561387 | Map |
| OH | Blanchard Valley Hospital | Findlay45840 | NCT03937635 | Map |
| OH | Blanchard Valley Hospital | Findlay45840 | NCT05561387 | Map |
| OH | Orion Cancer Care | Findlay45840 | NCT05561387 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT03937635 | Map |
| OH | Dayton Physicians LLC-Atrium | Franklin45005 | NCT03937635 | Map |
| OH | Dayton Physicians LLC-Atrium | Franklin45005 | NCT05561387 | Map |
| OH | Dayton Physicians LLC-Wayne | Greenville45331 | NCT05561387 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT03937635 | Map |
| OH | Wayne Hospital | Greenville45331 | NCT03937635 | Map |
| OH | Wayne Hospital | Greenville45331 | NCT05561387 | Map |
| OH | Mount Carmel Grove City Hospital | Grove City43123 | NCT03937635 | Map |
| OH | Greater Dayton Cancer Center | Kettering45409 | NCT03937635 | Map |
| OH | Greater Dayton Cancer Center | Kettering45409 | NCT05561387 | Map |
| OH | Kettering Medical Center | Kettering45429 | NCT03937635 | Map |
| OH | Kettering Medical Center | Kettering45429 | NCT05561387 | Map |
| OH | Saint Rita's Medical Center | Lima45801 | NCT03937635 | Map |
| OH | OhioHealth Mansfield Hospital | Mansfield44903 | NCT03937635 | Map |
| OH | OhioHealth Mansfield Hospital | Mansfield44903 | NCT04566328 | Map |
| OH | Marietta Memorial Hospital | Marietta45750 | NCT03937635 | Map |
| OH | OhioHealth Marion General Hospital | Marion43302 | NCT03937635 | Map |
| OH | OhioHealth Marion General Hospital | Marion43302 | NCT04566328 | Map |
| OH | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor44060 | NCT03937635 | Map |
| OH | UH Seidman Cancer Center at Southwest General Hospital | Middleburg Heights44130 | NCT03937635 | Map |
| OH | Mount Carmel New Albany Surgical Hospital | New Albany43054 | NCT03937635 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT03937635 | Map |
| OH | Newark Radiation Oncology | Newark43055 | NCT03937635 | Map |
| OH | Mercy Health - Perrysburg Hospital | Perrysburg43551 | NCT03937635 | Map |
| OH | OhioHealth Pickerington Methodist Hospital | Pickerington43147 | NCT04566328 | Map |
| OH | Southern Ohio Medical Center | Portsmouth45662 | NCT03937635 | Map |
| OH | UH Seidman Cancer Center at Firelands Regional Medical Center | Sandusky44870 | NCT03937635 | Map |
| OH | Springfield Regional Cancer Center | Springfield45504 | NCT03937635 | Map |
| OH | Springfield Regional Medical Center | Springfield45504 | NCT03937635 | Map |
| OH | Dayton Physicians LLC - Troy | Troy45373 | NCT05561387 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT03937635 | Map |
| OH | Saint Joseph Warren Hospital | Warren44484 | NCT03937635 | Map |
| OH | Saint Joseph Warren Hospital | Warren44484 | NCT05561387 | Map |
| OH | OhioHealth Westerville Medical Campus/Westerville Cancer Center | Westerville43082 | NCT04566328 | Map |
| OH | Saint Ann's Hospital | Westerville43081 | NCT03937635 | Map |
| OH | UH Seidman Cancer Center at Saint John Medical Center | Westlake44145 | NCT03937635 | Map |
| OH | Cleveland Clinic Wooster Family Health and Surgery Center | Wooster44691 | NCT03937635 | Map |
| OH | Saint Elizabeth Youngstown Hospital | Youngstown44501 | NCT03937635 | Map |
| OH | Saint Elizabeth Youngstown Hospital | Youngstown44501 | NCT05561387 | Map |
| OH | Genesis Healthcare System Cancer Care Center | Zanesville43701 | NCT03937635 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT03937635 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT04566328 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT05561387 | Map |
| OK | Oklahoma Cancer Specialists and Research Institute-Tulsa | Tulsa74146 | NCT03937635 | Map |
| OR | Saint Alphonsus Cancer Care Center-Baker City | Baker City97814 | NCT04566328 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT03937635 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT05561387 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT03937635 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT05561387 | Map |
| OR | Providence Cancer Institute Clackamas Clinic | Clackamas97015 | NCT05561387 | Map |
| OR | Bay Area Hospital | Coos Bay97420 | NCT03937635 | Map |
| OR | Bay Area Hospital | Coos Bay97420 | NCT05561387 | Map |
| OR | Willamette Valley Cancer Institute and Research Center /ID# 278721 | Eugene97401 | NCT07095452 | Map |
| OR | Rogue Valley Medical Center | Medford97504 | NCT05561387 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT03937635 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05561387 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT06022939 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT04566328 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT03937635 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05561387 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT06022939 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT03937635 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05561387 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT06022939 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT03937635 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05561387 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT06022939 | Map |
| OR | Saint Charles Health System-Redmond | Redmond97756 | NCT05561387 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT03937635 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT04566328 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05561387 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT03937635 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT04566328 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT05561387 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT03937635 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT05561387 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT06022939 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT03937635 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT04566328 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT05561387 | Map |
| PA | Penn State Health Medical Group - Andrews Patel Hematology/Oncology East | Harrisburg17111 | NCT04566328 | Map |
| PA | Geisinger Medical Center-Cancer Center Hazleton | Hazleton18201 | NCT03937635 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT04566328 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT05561387 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033-0850 | NCT03937635 | Map |
| PA | Penn State Milton S Hershey Medical Ctr | Hershey17033 | NCT05552222 | Map |
| PA | Lancaster General Health | Lancaster17601 | NCT03899155 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT03937635 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT05561387 | Map |
| PA | Lewistown Hospital | Lewistown17044 | NCT03937635 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT04972942 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06615479 | Map |
| PA | Penn Medicine - Abramson Cancer Center Perelman | Philadelphia19104 | NCT04068597 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT06022939 | Map |
| PA | University of Pennsylvania | Philadelphia19104 | NCT04139304 | Map |
| PA | University of Pennsylvania/Abramson Cancer Center | Philadelphia19104 | NCT06022939 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT03937635 | Map |
| PA | Allegheny Health Network | Pittsburgh15224 | NCT05552222 | Map |
| PA | West Penn Hospital | Pittsburgh15224 | NCT03937635 | Map |
| PA | Geisinger Cancer Services-Pottsville | Pottsville17901 | NCT03937635 | Map |
| PA | Penn State Health Saint Joseph Medical Center | Reading19605 | NCT04566328 | Map |
| PA | Community Medical Center | Scranton18510 | NCT05561387 | Map |
| PA | Geisinger Medical Oncology-Selinsgrove | Selinsgrove17870 | NCT03937635 | Map |
| PA | Reading Hospital | West Reading19611 | NCT03937635 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT03937635 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT05561387 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT06022939 | Map |
| RI | GSK Investigational Site | Providence02903 | NCT06679101 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT05552222 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT06119685 | Map |
| RI | Smilow Cancer Hospital Care Center - Westerly | Westerly02891 | NCT03937635 | Map |
| RI | Smilow Cancer Hospital Care Center - Westerly | Westerly02891 | NCT05561387 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT05561387 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT03937635 | Map |
| SC | MUSC-Hollings Cancer Center | Charleston29425 | NCT05552222 | Map |
| SC | Ralph H Johnson VA Medical Center | Charleston29401 | NCT04566328 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT05561387 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT05561387 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT03937635 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT05561387 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT03937635 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT05561387 | Map |
| SC | Prisma Health Greenville Memorial Hospital | Greenville29605 | NCT03937635 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT03937635 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT05561387 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT03937635 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT05561387 | Map |
| SD | Avera Cancer Institute-Aberdeen | Aberdeen57401 | NCT05561387 | Map |
| SD | Rapid City Regional Hospital | Rapid City57701 | NCT03937635 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT05561387 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05561387 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05561387 | Map |
| SD | Avera Cancer Institute at Yankton | Yankton57078 | NCT05561387 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT06022939 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT06022939 | Map |
| TN | Henry-Joyce Cancer Clinic | Nashville37232 | NCT05552222 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06119685 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06974786 | Map |
| TN | SCRI Oncology Partners /ID# 278353 | Nashville37203 | NCT07095452 | Map |
| TN | Tennesse Oncology | Nashville37203 | NCT03899155 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT03937635 | Map |
| TX | GSK Investigational Site | Austin78705 | NCT06679101 | Map |
| TX | GSK Investigational Site | Austin78712 | NCT06679101 | Map |
| TX | Houston Methodist San Jacinto Hospital | Baytown77521 | NCT03937635 | Map |
| TX | Houston Methodist San Jacinto Hospital | Baytown77521 | NCT06022939 | Map |
| TX | MD Anderson in The Woodlands | Conroe77384 | NCT03937635 | Map |
| TX | MD Anderson in The Woodlands | Conroe77384 | NCT05561387 | Map |
| TX | Houston Methodist Cypress Hospital | Cypress77429 | NCT06022939 | Map |
| TX | University of Texas - Southwestern Medical Center /ID# 271914 | Dallas75235 | NCT06953960 | Map |
| TX | University of Texas Southwestern | Dallas75390 | NCT05137054 | Map |
| TX | University of Texas Southwestern | Dallas75390 | NCT06974786 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75235 | NCT05552222 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT03937635 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT03937635 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT03937635 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT05561387 | Map |
| TX | Ben Taub General Hospital | Houston77030 | NCT05561387 | Map |
| TX | Houston Methodist Hospital | Houston77030 | NCT03937635 | Map |
| TX | Houston Methodist Hospital | Houston77030 | NCT05552222 | Map |
| TX | Houston Methodist Hospital | Houston77030 | NCT06022939 | Map |
| TX | Houston Methodist West Hospital | Houston77094 | NCT03937635 | Map |
| TX | Houston Methodist West Hospital | Houston77094 | NCT06022939 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT03937635 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05561387 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT06022939 | Map |
| TX | MD Anderson West Houston | Houston77079 | NCT03937635 | Map |
| TX | MD Anderson West Houston | Houston77079 | NCT05561387 | Map |
| TX | Methodist Willowbrook Hospital | Houston77070 | NCT03937635 | Map |
| TX | Methodist Willowbrook Hospital | Houston77070 | NCT06022939 | Map |
| TX | Michael E DeBakey VA Medical Center | Houston77030 | NCT05561387 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT04139304 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT06119685 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT06615479 | Map |
| TX | UT MD Anderson | Houston77030 | NCT07513129 | Map |
| TX | GSK Investigational Site | Kingwood77339 | NCT06679101 | Map |
| TX | MD Anderson League City | League City77573 | NCT03937635 | Map |
| TX | MD Anderson League City | League City77573 | NCT05561387 | Map |
| TX | Joe Arrington Cancer Research Treatment Center | Lubbock79410 | NCT05552222 | Map |
| TX | Houston Methodist Saint John Hospital | Nassau Bay77058 | NCT03937635 | Map |
| TX | Houston Methodist Saint John Hospital | Nassau Bay77058 | NCT06022939 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT03937635 | Map |
| TX | GSK Investigational Site | San Antonio78240 | NCT06679101 | Map |
| TX | University of Texas Health Science Center at San Antonio | San Antonio78229 | NCT05561387 | Map |
| TX | Houston Methodist Sugar Land Hospital | Sugar Land77479 | NCT03937635 | Map |
| TX | Houston Methodist Sugar Land Hospital | Sugar Land77479 | NCT06022939 | Map |
| TX | MD Anderson in Sugar Land | Sugar Land77478 | NCT03937635 | Map |
| TX | MD Anderson in Sugar Land | Sugar Land77478 | NCT05561387 | Map |
| TX | Houston Methodist The Woodlands Hospital | The Woodlands77385 | NCT03937635 | Map |
| TX | Houston Methodist The Woodlands Hospital | The Woodlands77385 | NCT06022939 | Map |
| TX | Texas Oncology - The Woodlands /ID# 278726 | The Woodlands77380 | NCT07095452 | Map |
| TX | GSK Investigational Site | Tyler75702 | NCT06679101 | Map |
| TX | Texas Oncology - Northeast Texas /ID# 278725 | Tyler75702 | NCT07095452 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112-5550 | NCT04973605 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT05552222 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT06615479 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT03937635 | Map |
| UT | Utah Cancer Specialists | Salt Lake City84106 | NCT05552222 | Map |
| VT | White River Junction Veteran Administration Medical Center | White River Junction05009 | NCT04566328 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT03937635 | Map |
| VA | GSK Investigational Site | Fairfax22031 | NCT06679101 | Map |
| VA | NEXT Oncology Virginia | Fairfax22031 | NCT06119685 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 278716 | Fairfax22031 | NCT07095452 | Map |
| VA | Alexander T. Augusta Military Medical Center | Fort Belvoir22060 | NCT05552222 | Map |
| VA | Sovah Health Martinsville | Martinsville24115 | NCT05561387 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT06974786 | Map |
| VA | Virginia Oncology Associates Brock Cancer Center | Norfolk23502 | NCT05552222 | Map |
| VA | Richmond VA Medical Center | Richmond23249 | NCT05552222 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT05561387 | Map |
| VA | Virginia Cancer Institute | Richmond23229 | NCT05561387 | Map |
| VA | Virginia Commonwealth University Medical Center | Richmond23298 | NCT05552222 | Map |
| VA | Virginia Commonwealth University/Massey Cancer Center | Richmond23298 | NCT05561387 | Map |
| VA | Blue Ridge Cancer Care - Roanoke /ID# 278722 | Roanoke24014 | NCT07095452 | Map |
| VA | VCU Community Memorial Health Center | South Hill23970 | NCT05561387 | Map |
| WA | Providence Regional Cancer System-Aberdeen | Aberdeen98520 | NCT03937635 | Map |
| WA | Providence Regional Cancer System-Aberdeen | Aberdeen98520 | NCT05561387 | Map |
| WA | PeaceHealth Saint Joseph Medical Center | Bellingham98225 | NCT03937635 | Map |
| WA | PeaceHealth Saint Joseph Medical Center | Bellingham98225 | NCT05561387 | Map |
| WA | Harrison Medical Center | Bremerton98310 | NCT05561387 | Map |
| WA | Providence Regional Cancer System-Centralia | Centralia98531 | NCT03937635 | Map |
| WA | Providence Regional Cancer System-Centralia | Centralia98531 | NCT05561387 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT03937635 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05561387 | Map |
| WA | Providence Regional Cancer Partnership | Everett98201 | NCT03937635 | Map |
| WA | Providence Regional Cancer Partnership | Everett98201 | NCT05561387 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT03937635 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05561387 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT03937635 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT05561387 | Map |
| WA | FHCC at EvergreenHealth | Kirkland98034 | NCT03937635 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT03937635 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT05561387 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT03937635 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT05561387 | Map |
| WA | Skagit Regional Health Cancer Care Center | Mount Vernon98274 | NCT03937635 | Map |
| WA | GSK Investigational Site | Puyallup98373 | NCT06679101 | Map |
| WA | Valley Medical Center | Renton98055 | NCT03937635 | Map |
| WA | FHCC at Northwest Hospital | Seattle98133 | NCT03937635 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT03937635 | Map |
| WA | Research Site | Seattle98104 | NCT07391657 | Map |
| WA | Swedish Medical Center-Ballard Campus | Seattle98107 | NCT03937635 | Map |
| WA | Swedish Medical Center-Ballard Campus | Seattle98107 | NCT05561387 | Map |
| WA | Swedish Medical Center-Cherry Hill | Seattle98122-5711 | NCT03937635 | Map |
| WA | Swedish Medical Center-Cherry Hill | Seattle98122-5711 | NCT05561387 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT03937635 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05561387 | Map |
| WA | University of Washington | Seattle98195 | NCT04973605 | Map |
| WA | University of Washington Medical Center - Montlake | Seattle98195 | NCT03937635 | Map |
| WA | VA Puget Sound Health Care System | Seattle98108 | NCT05137054 | Map |
| WA | PeaceHealth United General Medical Center | Sedro-Woolley98284 | NCT03937635 | Map |
| WA | PeaceHealth United General Medical Center | Sedro-Woolley98284 | NCT05561387 | Map |
| WA | Providence Regional Cancer System-Shelton | Shelton98584 | NCT05561387 | Map |
| WA | Saint Michael Cancer Center | Silverdale98383 | NCT03937635 | Map |
| WA | Saint Michael Cancer Center | Silverdale98383 | NCT04566328 | Map |
| WA | Cancer Care Northwest - Spokane South | Spokane99202 | NCT03937635 | Map |
| WA | Cancer Care Northwest-North Spokane | Spokane99218 | NCT03937635 | Map |
| WA | Northwest Medical Specialties Tacoma /ID# 272506 | Tacoma98405 | NCT06953960 | Map |
| WA | NorthWest Medical Specialties, PLLC | Tacoma98405 | NCT05552222 | Map |
| WA | PeaceHealth Southwest Medical Center | Vancouver98664 | NCT03937635 | Map |
| WA | PeaceHealth Southwest Medical Center | Vancouver98664 | NCT05561387 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT03937635 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT05561387 | Map |
| WA | North Star Lodge Cancer Center at Yakima Valley Memorial Hospital | Yakima98902 | NCT03937635 | Map |
| WA | Providence Regional Cancer System-Yelm | Yelm98597 | NCT05561387 | Map |
| WV | United Hospital Center | Bridgeport26330 | NCT03937635 | Map |
| WV | West Virginia University Charleston Division | Charleston25304 | NCT03937635 | Map |
| WV | West Virginia University Charleston Division | Charleston25304 | NCT05561387 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT03937635 | Map |
| WV | Camden Clark Medical Center | Parkersburg26101 | NCT03937635 | Map |
| WV | Wheeling Hospital/Schiffler Cancer Center | Wheeling26003 | NCT03937635 | Map |
| WI | Langlade Hospital and Cancer Center | Antigo54409 | NCT05561387 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT03937635 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT04566328 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT05561387 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT03937635 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05561387 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT03937635 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT05561387 | Map |
| WI | Aurora Cancer Care-Southern Lakes VLCC | Burlington53105 | NCT03937635 | Map |
| WI | Marshfield Clinic-Chippewa Center | Chippewa Falls54729 | NCT05561387 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT03937635 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05561387 | Map |
| WI | Aurora Health Center-Fond du Lac | Fond du Lac54937 | NCT03937635 | Map |
| WI | Aurora Health Care Germantown Health Center | Germantown53022 | NCT03937635 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT03937635 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT03937635 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT03937635 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT04566328 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT06022939 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT03937635 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT04566328 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT06022939 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT03937635 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT05561387 | Map |
| WI | Mercyhealth Hospital and Cancer Center - Janesville | Janesville53548 | NCT03937635 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Johnson Creek | Johnson Creek53038 | NCT03937635 | Map |
| WI | Aurora Cancer Care-Kenosha South | Kenosha53142 | NCT03937635 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT03937635 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT04566328 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05561387 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT06022939 | Map |
| WI | Marshfield Clinic - Ladysmith Center | Ladysmith54848 | NCT05561387 | Map |
| WI | University of Wisconsin Carbone Cancer Center | Madison53792-0001 | NCT04973605 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT03937635 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT06022939 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT03937635 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT04566328 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT06022939 | Map |
| WI | University of Wisconsin Clinical Science Center | Madison53792 | NCT06974786 | Map |
| WI | William S Middleton VA Medical Center | Madison53705 | NCT04566328 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT03937635 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT03937635 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05561387 | Map |
| WI | Aspirus Medford Hospital | Medford54451 | NCT05561387 | Map |
| WI | Aurora Cancer Care-Milwaukee | Milwaukee53209 | NCT03937635 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT03937635 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT03937635 | Map |
| WI | Froedtert Hospital & the Medical College of Wisconsin | Milwaukee53226 | NCT05451771 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226-1222 | NCT04973605 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06022939 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06615479 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06974786 | Map |
| WI | Marshfield Clinic-Minocqua Center | Minocqua54548 | NCT05561387 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT03937635 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT03937635 | Map |
| WI | ThedaCare Regional Medical Center - Neenah | Neenah54956 | NCT04566328 | Map |
| WI | Marshfield Medical Center - Neillsville | Neillsville54456 | NCT05561387 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT03937635 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT04566328 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT05561387 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT03937635 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT03937635 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT04566328 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT06022939 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT03937635 | Map |
| WI | Aurora Cancer Care-Racine | Racine53406 | NCT03937635 | Map |
| WI | Ascension Saint Mary's Hospital | Rhinelander54501 | NCT05561387 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT03937635 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT05561387 | Map |
| WI | ThedaCare Cancer Care - Shawano | Shawano54166 | NCT03937635 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT06022939 | Map |
| WI | Sheboygan Physicians Group | Sheboygan53081 | NCT06022939 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT03937635 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT03937635 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT05561387 | Map |
| WI | Ascension Saint Michael's Hospital | Stevens Point54481 | NCT05561387 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT03937635 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05561387 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT03937635 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT04566328 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT06022939 | Map |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT03937635 | — |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT03937635 | Map |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT05561387 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT03937635 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT03937635 | Map |
| WI | Aspirus Regional Cancer Center | Wausau54401 | NCT05561387 | Map |
| WI | Marshfield Clinic-Wausau Center | Wausau54401 | NCT05561387 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT03937635 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT03937635 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT03937635 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05561387 | Map |
| WI | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids54494 | NCT05561387 | Map |
| WI | Marshfield Clinic - Wisconsin Rapids Center | Wisconsin Rapids54494 | NCT05561387 | Map |
| WY | Memorial Hospital of Laramie County | Cheyenne82001 | NCT03937635 | Map |
Daratumumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | suspended | not yet recruiting | unknown | approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 3 | 1 | 1 | 5 | |||||||
| P1 | 8 | 9 | 21 | 8 | 3 | 2 | 1 | 52 | |||
| P1/P2 | 9 | 7 | 11 | 6 | 4 | 3 | 2 | 42 | |||
| P2 | 32 | 44 | 1 | 33 | 16 | 11 | 1 | 8 | 15 | 161 | |
| P2/P3 | 2 | 1 | 2 | 2 | 7 | ||||||
| P3 | 23 | 15 | 12 | 2 | 2 | 1 | 2 | 57 | |||
| P4 | 3 | 2 | 2 | 7 | |||||||
| N/A | 5 | 3 | 1 | 5 | 2 | 16 |
Recruiting Daratumumab clinical trials (104)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06358638 | SUN-RAYSickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody | P2 | Sickle Cell Disease | 12 | Apr 2024 |
| NCT07095452 | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | P2/P3 | Multiple Myeloma | 660 | Jan 2026 |
| NCT07428369 | LINKER-MM8A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) | P2/P3 | Multiple Myeloma (MM) | 1,570 | Jun 2026 |
| NCT06187441 | HOVON174MMFeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) | P3 | Multiple Myeloma | 599 | May 2024 |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | P3 | Multiple Myeloma | 1,000 | Dec 2025 |
| NCT06918002 | ElLenElranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients | P3 | Multiple Myeloma, Newly Diagnosed | 824 | Jul 2025 |
| NCT06892522 | AEA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | P1/P2 | Multiple Myeloma | 440 | Jun 2025 |
| NCT07247097 | ELDORADOELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma | P2 | Multiple Myeloma | 160 | Apr 2026 |
| NCT05907759 | Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease | P2 | Lymphoma, Primary Effusion | 28 | Jul 2024 |
| NCT07072585 | T-ALLTesting the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | P2/P3 | Stage II T Lymphoblastic Leukemia/Lymphoma | 1,708 | Aug 2026 |
| NCT05137054 | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | P1 | Multiple Myeloma | 317 | Aug 2022 |
| NCT07222761 | LINKER-MM5A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | P3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | 915 | Jan 2026 |
| NCT07285239 | PrE1005Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | P3 | Multiple Myeloma | 500 | Jul 2026 |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | P2 | Multiple Myeloma (MM) | 150 | Dec 2025 |
| NCT07110844 | Teclistamab-Daratumumab in AL Amyloidosis | P2 | Amyloid Light-chain Amyloidosis | 25 | Nov 2025 |
| NCT05552222 | MajesTEC-7A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | P3 | Multiple Myeloma | 1,590 | Oct 2022 |
| NCT05623020 | MagnetisMM-6A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | P3 | Multiple Myeloma | 1,116 | Nov 2022 |
| NCT07393282 | LINKER-SMM2A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) | P3 | High Risk Smoldering Multiple Myeloma (HR-SMM) | 270 | May 2026 |
| NCT06974786 | FASTERFrontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma | P2 | Multiple Myeloma, Newly Diagnosed | 100 | Aug 2025 |
| NCT07555938 | CEVOLUTIONCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | P3 | Multiple Myeloma | 380 | Jun 2026 |
| NCT07605416 | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial | P2 | Plasma Cell Leukemia | 74 | Jul 2026 |
| NCT07075510 | Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders | P1/P2 | Plasma Cell Disorder | 30 | Oct 2025 |
| NCT06182774 | Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma | P3 | Multiple Myeloma | 570 | Apr 2024 |
| NCT06615479 | QUINTESSENTIAL-2A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | P3 | Relapsed or Refractory Multiple Myeloma (RRMM) | 440 | Mar 2025 |
| NCT04513639 | REMNANTThe Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study | P2/P3 | Multiple Myeloma | 176 | Aug 2020 |
| NCT07029776 | MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma | P2 | Multiple Myeloma (MM) | 50 | Jul 2026 |
| NCT07513129 | Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma | P1 | T-cell Acute Lymphoblastic Leukemia | 18 | Jun 2026 |
| NCT06931704 | IFM 2024_06Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) | P2 | Multiple Myeloma | 176 | May 2025 |
| NCT06413498 | iMMagine-3A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | P3 | Multiple Myeloma | 450 | Aug 2024 |
| NCT05561387 | NDMMComparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | P3 | Plasma Cell Myeloma | 510 | Oct 2023 |
| NCT06679101 | DREAMM-10A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | P3 | Multiple Myeloma | 520 | Dec 2024 |
| NCT06785415 | Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma | P1/P2 | Recurrent Multiple Myeloma | 37 | Mar 2025 |
| NCT05896228 | Iber-KDdIberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | P2 | Refractory Multiple Myeloma | 30 | Feb 2024 |
| NCT06953960 | MMA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | P1/P2 | Multiple Myeloma | 199 | Jul 2025 |
| NCT06464991 | FUMANBA-03A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) | P3 | Multiple Myeloma | 240 | Mar 2024 |
| NCT06022939 | Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis | P3 | AL Amyloidosis | 338 | Jul 2024 |
| NCT05572229 | IFM2021-01Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | P2 | Multiple Myeloma | 74 | Dec 2023 |
| NCT04139304 | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | Early P1 | Plasmablastic Lymphoma | 15 | May 2021 |
| NCT07391657 | DURGA-4A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) | P3 | Relapsed Refractory Multiple Myeloma | 508 | Feb 2026 |
| NCT06622005 | SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | P1 | Recurrent Multiple Myeloma | 15 | Apr 2025 |
| NCT07221032 | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma | P1 | Relapse Multiple Myeloma | 12 | Jul 2026 |
| NCT07452198 | A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma | P3 | Multiple Myeloma | 358 | Mar 2026 |
| NCT07045909 | GEM-AnitoFIRSTEfficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) | P2 | De Novo Multiple Myeloma | 30 | Jun 2025 |
| NCT06100237 | REVIVETeclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) | P2 | Multiple Myeloma | 50 | Dec 2023 |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | P1/P2 | NHL | 128 | Oct 2023 |
| NCT05438043 | A Study of Daratumumab | P3 | Multiple Myeloma | 500 | Dec 2022 |
| NCT03937635 | Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | P3 | Smoldering Plasma Cell Myeloma | 288 | Sep 2019 |
| NCT05695508 | HD10/DSMMXXGMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | P2 | Multiple Myeloma | 160 | Dec 2022 |
| NCT03899155 | Pan Tumor Rollover Study | P2 | Cancer | 1,500 | Aug 2019 |
| NCT06952478 | A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | P3 | Refractory or Relapsed Multiple Myeloma | 486 | Aug 2025 |
| NCT07485647 | Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing | P2 | Multiple Myeloma | 50 | May 2026 |
| NCT07110662 | NET-CD38New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. | P1/P2 | Toxic Epidermal Necrolysis | 9 | Oct 2025 |
| NCT07341867 | Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | P1 | Multiple Myeloma | 90 | Jun 2026 |
| NCT07335887 | Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis | P2 | AL Amyloidosis (AL) | 39 | Jan 2026 |
| NCT06636552 | EUMELEIAAn Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L | P2 | Primary Plasma Cell Leukemia | 43 | Nov 2021 |
| NCT07287228 | DARA-AA-001The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia | P1/P2 | Aplastic Anemia | 37 | Dec 2025 |
| NCT06042725 | MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | P1 | Multiple Myeloma | 100 | Mar 2024 |
| NCT07234019 | ITPRituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | Immune Thrombocytopenia | 160 | Jan 2026 |
| NCT06768489 | A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma | P1 | Multiple Myeloma | 140 | Dec 2024 |
| NCT06505369 | TALTECBispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | P2 | Multiple Myeloma | 50 | Jun 2024 |
| NCT04972942 | ALLO-T-DARTTargeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma | P1 | T-cell Acute Lymphoblastic Leukemia | 30 | May 2023 |
| NCT07018050 | Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | P2 | Relapsed or Refractory Multiple Myeloma | 160 | Sep 2025 |
| NCT06287944 | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | P1 | Acute Lymphoblastic Leukemia | 15 | Jul 2025 |
| NCT07362238 | ITPDaratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) | P2 | Immune Thrombocytopenia | 122 | Mar 2026 |
| NCT05054478 | PCL-2Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation | P2 | Plasma Cell Leukemia | 29 | Oct 2021 |
| NCT06948084 | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse | P2 | Recurrent Multiple Myeloma | 80 | Aug 2026 |
| NCT06827860 | Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | P2 | Multiple Myeloma in Relapse | 23 | Nov 2025 |
| NCT06697483 | Risk Stratification and MRD-driven Maintenance for MM After ASCT | N/A | Multiple Myeloma | 100 | Dec 2024 |
| NCT06409702 | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | P4 | Newly Diagnosed | 59 | Jun 2024 |
| NCT04566328 | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | P3 | Plasma Cell Myeloma | 1,450 | Feb 2021 |
| NCT07297563 | ITPAnti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | Immune Thrombocytopenia | 160 | Jan 2026 |
| NCT06867991 | RADIASafety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis | P3 | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 200 | Nov 2024 |
| NCT06142396 | Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure | Early P1 | Multiple Myeloma | 30 | Nov 2024 |
| NCT05849740 | AHA2023An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A | P4 | Acquired Hemophilia | 25 | May 2023 |
| NCT06140966 | Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | P2 | Multiple Myeloma | 54 | Oct 2023 |
| NCT04915248 | FIL_DALYAStudy to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. | P2 | Plasmablastic Lymphoma | 28 | Jul 2022 |
| NCT06015724 | DARANIVOVAXAnti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | P2 | Pancreatic Ductal Adenocarcinoma | 54 | Jan 2024 |
| NCT06889948 | DAMOCLESThe Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland | P2 | Kidney Failure | 30 | Jan 2024 |
| NCT05289687 | Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL | P2 | T-cell Acute Lymphoblastic Leukemia | 20 | May 2023 |
| NCT05020236 | MAGNETISMM-5A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | P3 | Multiple Myeloma | 944 | Oct 2021 |
| NCT07362199 | ITPAnti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | Immune Thrombocytopenia | 20 | Mar 2026 |
| NCT06398457 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | Early P1 | Hematologic Malignancy | 8 | Sep 2024 |
| NCT06192979 | Optimize First-line Treatment for AL Amyloidosis With t (11; 14) | N/A | Amyloidosis; Systemic | 41 | Jan 2024 |
| NCT05671757 | DARE-APSDaratumumab in Primary Antiphospholipid Syndrome | P1/P2 | Autoimmune Disorders | 22 | May 2023 |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | P1/P2 | Haematological Malignancy | 250 | Aug 2019 |
| NCT05363111 | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | P1 | Recurrent Plasma Cell Myeloma | 15 | Nov 2022 |
| NCT07081126 | DARTABMRDaratumumab for Late Antibody-Mediated Rejection | N/A | Kidney Tansplant | 20 | Jul 2025 |
| NCT06107738 | IBEXIberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma | P2 | Multiple Myeloma | 60 | Dec 2023 |
| NCT05888870 | ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor | P4 | Hemophilia A With Inhibitor | 50 | Nov 2023 |
| NCT05898646 | Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial | P2 | AL Amyloidosis | 96 | Jul 2023 |
| NCT04973605 | BGB-11417A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | P1/P2 | Relapsed/Refractory Multiple Myeloma | 246 | Sep 2021 |
| NCT07026604 | CCM-DS01Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study | Early P1 | Cavernous Malformation, Cerebral | 10 | Jul 2025 |
| NCT06083922 | MGRSA Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) | P2 | Multiple Myeloma | 20 | Oct 2023 |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | P1/P2 | Multiple Myeloma | 48 | Oct 2022 |
| NCT06629818 | Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) | P2 | Light Chain (AL) Amyloidosis | 36 | Oct 2024 |
| NCT07015021 | DKPDThe Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients | N/A | Multiple Myeloma | 72 | Jun 2025 |
| NCT05451771 | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | P1/P2 | AL Amyloidosis | 53 | Oct 2022 |
| NCT07063199 | ITPAnti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) | P2 | Immune Thrombocytopenia | 30 | Aug 2025 |
| NCT06838962 | ITPAnti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) | P2 | Immune Thrombocytopenia | 30 | Aug 2024 |
| NCT05654506 | Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits | P2 | Proliferative Glomerulonephritis With Monoclonal IgG Deposits | 40 | Aug 2023 |
| NCT05300451 | Daratumumab in HLA Desensitization Prior to Transplantation | P2 | Cardiac Transplant | 10 | Mar 2022 |
| NCT07021677 | DARA_T_ALLUse of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" | P2 | T Acute Lymphoblastic Leukemia | 18 | Aug 2023 |
| NCT06483139 | Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy | — | Multiple Myeloma | 450 | Jun 2024 |
| NCT06455748 | Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study | N/A | Amyloid Light-chain Amyloidosis | 20 | Mar 2024 |
Daratumumab clinical trials by indication
Multiple Myeloma (157)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07095452 | — | P2/P3 | recruiting | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant |
| NCT05257083 | CARTITUDE-6 | P3 | active not recruiting | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma |
| NCT04071457 | DRAMMATIC | P3 | active not recruiting | S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration |
| NCT06187441 | HOVON174MM | P3 | recruiting | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) |
| NCT06932562 | — | P3 | recruiting | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant |
| NCT06892522 | AE | P1/P2 | recruiting | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib |
| NCT07247097 | ELDORADO | P2 | not yet recruiting | ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma |
| NCT05137054 | — | P1 | recruiting | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments |
| + 149 more, see All trials below. | ||||
Plasma Cell Myeloma (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05561387 | NDMM | P3 | recruiting | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment |
| NCT05392946 | — | P1/P2 | active not recruiting | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study |
| NCT04566328 | — | P3 | recruiting | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial |
| NCT03942224 | DeRIVE | P2 | active not recruiting | Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma |
| NCT03346135 | — | P2 | active not recruiting | Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma |
| NCT03477539 | — | P2 | completed | Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma |
| NCT05511428 | — | P4 | completed | Home Based Daratumumab Administration for Patients With Multiple Myeloma |
| NCT04892264 | — | P1 | terminated | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma |
| + 3 more, see All trials below. | ||||
Recurrent Plasma Cell Myeloma (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04756401 | — | P2 | active not recruiting | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma |
| NCT03763162 | — | P2 | active not recruiting | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| NCT05363111 | — | P1 | recruiting | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma |
| NCT03622775 | — | P2 | terminated | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant |
| NCT01415882 | — | P2 | completed | Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib |
| NCT03311828 | — | P1 | completed | Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma |
| NCT04407442 | — | P2 | terminated | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab |
| NCT04956302 | — | P1 | terminated | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma |
| + 3 more, see All trials below. | ||||
Immune Thrombocytopenia (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07234019 | ITP | P2 | recruiting | Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) |
| NCT07362238 | ITP | P2 | recruiting | Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) |
| NCT07297563 | ITP | P2 | recruiting | Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) |
| NCT07362199 | ITP | P2 | recruiting | Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) |
| NCT07063199 | ITP | P2 | recruiting | Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) |
| NCT06838962 | ITP | P2 | recruiting | Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) |
| NCT05562882 | — | P2 | unknown | A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia |
AL Amyloidosis (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06022939 | — | P3 | recruiting | Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis |
| NCT05486481 | ALTITUDE | P1/P2 | withdrawn | Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) |
| NCT05898646 | — | P2 | recruiting | Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial |
| NCT05451771 | — | P1/P2 | recruiting | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis |
| NCT04895917 | DarPAL | P2 | terminated | Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis |
| NCT04304144 | — | P2 | completed | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis |
| NCT02841033 | — | P1/P2 | completed | Daratumumab for the Treatment of Patients With AL Amyloidosis |
Relapsed/Refractory Multiple Myeloma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05259839 | IV | P1 | active not recruiting | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma |
| NCT04973605 | BGB-11417 | P1/P2 | recruiting | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma |
| NCT05857982 | — | P1/P2 | unknown | Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma |
| NCT05308654 | — | P1 | active not recruiting | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets |
| NCT03590652 | — | P2 | terminated | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma |
| NCT03450057 | DARE | P2 | completed | Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment |
Newly Diagnosed Multiple Myeloma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03742297 | — | P3 | active not recruiting | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years |
| NCT06348147 | — | P2 | withdrawn | Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation |
| NCT04052880 | — | P2 | active not recruiting | Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM |
| NCT05561049 | — | N/A | unknown | Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma |
| NCT05088330 | — | N/A | unknown | A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM |
Recurrent Multiple Myeloma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06785415 | — | P1/P2 | recruiting | Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma |
| NCT06622005 | — | P1 | recruiting | SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma |
| NCT06948084 | — | P2 | not yet recruiting | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse |
| NCT07082270 | — | P1 | withdrawn | Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma |
Multiple Myeloma in Relapse (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06827860 | — | P2 | recruiting | Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse |
| NCT04925193 | — | P2 | active not recruiting | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma |
| NCT03836014 | CONFIRM | P3 | active not recruiting | Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma |
| NCT03697629 | — | P2 | completed | A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma |
Relapsed or Refractory Multiple Myeloma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07018050 | — | P2 | recruiting | Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma |
| NCT05408026 | PVD-DARA | P1/P2 | withdrawn | Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM |
| NCT06055075 | — | P1/P2 | completed | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT03837509 | SC | P1/P2 | terminated | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma |
T-cell Acute Lymphoblastic Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07513129 | — | P1 | recruiting | Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma |
| NCT04972942 | ALLO-T-DART | P1 | recruiting | Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma |
| NCT05289687 | — | P2 | recruiting | Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL |
Multiple Myeloma (MM) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07428369 | LINKER-MM8 | P2/P3 | not yet recruiting | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) |
| NCT07107529 | — | P2 | recruiting | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. |
| NCT07029776 | — | P2 | not yet recruiting | MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma |
Plasma Cell Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07605416 | — | P2 | not yet recruiting | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial |
| NCT05054478 | PCL-2 | P2 | not yet recruiting | Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation |
| NCT03591744 | — | P1 | withdrawn | Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia |
Myeloma Multiple (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07085728 | — | P2 | active not recruiting | Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure |
| NCT03992170 | DART4MM | P2 | unknown | Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive |
| NCT04065789 | KyDaR | P2 | completed | Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients |
Amyloidosis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05250973 | AQUARIUS | P2 | active not recruiting | A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis |
| NCT03201965 | AL | P3 | completed | A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis |
| NCT02816476 | AMYDARA | P2 | completed | Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis |
Acute Myeloid Leukemia (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04714372 | — | P1 | completed | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia |
| NCT04614636 | — | P1 | terminated | FT538 in Subjects With Advanced Hematologic Malignancies |
| NCT02807558 | SY-1425 | P2 | completed | A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome |
Allosensitization (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04610320 | — | P1 | completed | Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation |
| NCT04204980 | DARDAR | P1/P2 | completed | Desensitization in Kidney Allograft Using Daratumumab |
| NCT04088903 | — | P1 | withdrawn | Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation |
Relapsed Refractory Multiple Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07391657 | DURGA-4 | P3 | recruiting | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) |
| NCT03732703 | MyDRUG | P1/P2 | completed | Myeloma-Developing Regimens Using Genomics (MyDRUG) |
Relapsed and/or Refractory Multiple Myeloma (RRMM) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07222761 | LINKER-MM5 | P3 | recruiting | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) |
| NCT04776018 | RRMM | P1/P2 | terminated | A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) |
Aplastic Anemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07287228 | DARA-AA-001 | P1/P2 | not yet recruiting | The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia |
| NCT05832216 | — | P1 | completed | Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia |
Amyloid Light-chain Amyloidosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07110844 | — | P2 | recruiting | Teclistamab-Daratumumab in AL Amyloidosis |
| NCT06455748 | — | N/A | recruiting | Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study |
Multiple Myeloma, Newly Diagnosed (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06918002 | ElLen | P3 | recruiting | Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients |
| NCT06974786 | FASTER | P2 | recruiting | Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma |
Relapsed or Refractory Multiple Myeloma (RRMM) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06615479 | QUINTESSENTIAL-2 | P3 | recruiting | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) |
| NCT04824794 | — | P1/P2 | terminated | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies |
Refractory Multiple Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05896228 | Iber-KDd | P2 | recruiting | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma |
| NCT03589222 | SELIBORDARA | P2 | active not recruiting | SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma |
Amyloidosis; Systemic (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06192979 | — | N/A | recruiting | Optimize First-line Treatment for AL Amyloidosis With t (11; 14) |
| NCT04474938 | — | P2 | unknown | Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis |
Plasmablastic Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04139304 | — | Early P1 | recruiting | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma |
| NCT04915248 | FIL_DALYA | P2 | recruiting | Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. |
Relapsed Multiple Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03158688 | CANDOR | P3 | completed | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. |
| NCT04649060 | LIGHTHOUSE | P3 | terminated | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma |
Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03500445 | — | P2 | active not recruiting | Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma |
| NCT03184194 | — | P2 | completed | Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide |
Smoldering Multiple Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03289299 | ASCENT | P2 | active not recruiting | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant |
| NCT03301220 | — | P3 | completed | A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma |
Relapse Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07221032 | — | P1 | not yet recruiting | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma |
Stage II T Lymphoblastic Leukemia/Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07072585 | T-ALL | P2/P3 | not yet recruiting | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) |
High Risk Smoldering Multiple Myeloma (HR-SMM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07393282 | LINKER-SMM2 | P3 | recruiting | A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) |
AL Amyloidosis (AL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07335887 | — | P2 | not yet recruiting | Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis |
ALL, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06570915 | T-ALL-2024 | P2 | withdrawn | Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy |
Microvascular Inflammation - MVI in Kindey Transplant Recipients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07274462 | DARA-MVI | P4 | active not recruiting | DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation) |
Toxic Epidermal Necrolysis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07110662 | NET-CD38 | P1/P2 | not yet recruiting | New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. |
Plasma Cell Disorder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07075510 | — | P1/P2 | recruiting | Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders |
Peripheral Neuropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06046287 | Dara-MGUS | P2 | withdrawn | Daratumumab for Polyneuropathy Associated With MGUS |
Refractory or Relapsed Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06952478 | — | P3 | recruiting | A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma |
Cavernous Malformation, Cerebral (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07026604 | CCM-DS01 | Early P1 | not yet recruiting | Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study |
Kidney Tansplant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07081126 | DARTABMR | N/A | recruiting | Daratumumab for Late Antibody-Mediated Rejection |
Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06287944 | — | P1 | recruiting | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome |
De Novo Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07045909 | GEM-AnitoFIRST | P2 | recruiting | Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) |
Anti-N-Methyl-D-Aspartate Receptor Encephalitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06867991 | RADIA | P3 | recruiting | Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis |
T-Lymphocytic Leukemia, Acute (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06253637 | DARATALL-VHR | P2 | active not recruiting | Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program |
Light Chain (AL) Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06629818 | — | P2 | recruiting | Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) |
Hematologic Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06398457 | — | Early P1 | recruiting | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies |
Acute Kidney Injury (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06549634 | — | N/A | completed | Biomarkers of AKI in Patients Receiving Daratumumab |
Lymphoma, Primary Effusion (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05907759 | — | P2 | recruiting | Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease |
Newly Diagnosed (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06409702 | — | P4 | recruiting | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection |
Sickle Cell Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06358638 | SUN-RAY | P2 | recruiting | Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody |
M-protein Related Cardiac Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06297681 | — | N/A | unknown | Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease |
Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06015724 | DARANIVOVAX | P2 | recruiting | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer |
Kidney Failure (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06889948 | DAMOCLES | P2 | recruiting | The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland |
Hemophilia A With Inhibitor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05888870 | — | P4 | recruiting | ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor |
NHL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06119685 | — | P1/P2 | recruiting | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers |
High-Risk de Novo Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05849610 | GEM-TECTAL | P2 | active not recruiting | Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma |
T Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07021677 | DARA_T_ALL | P2 | recruiting | Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" |
Proliferative Glomerulonephritis With Monoclonal IgG Deposits (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05654506 | — | P2 | recruiting | Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits |
Non-small Cell Lung Cancer With STK11/LKB1 Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05807048 | — | P2 | completed | Daratumumab in STK11 Mutated NSCLC |
Autoimmune Disorders (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05671757 | DARE-APS | P1/P2 | recruiting | Daratumumab in Primary Antiphospholipid Syndrome |
Antibody-mediated Rejection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05913596 | — | N/A | unknown | The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation |
Acquired Hemophilia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05849740 | AHA2023 | P4 | recruiting | An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A |
Immunoglobulin Light-chain Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05776940 | — | P3 | unknown | Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis |
Nephrotic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05704400 | — | P2 | unknown | Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome |
Neuromyelitis Optica (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05403138 | DAWN | P2/P3 | active not recruiting | Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders |
Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04922723 | PRIDE | P1/P2 | active not recruiting | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma |
ISS Stage III Plasma Cell Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05497804 | — | P2 | active not recruiting | Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial |
Cardiac Transplant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05300451 | — | P2 | enrolling by invitation | Daratumumab in HLA Desensitization Prior to Transplantation |
Hemolytic Anemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05004259 | DARA-AIHA | P1 | completed | The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia |
Sensitisation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05145296 | COMBAT | P2 | terminated | The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation |
Relapsed Hematologic Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05205252 | ARIA | P1/P2 | withdrawn | A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. |
Primary Plasma Cell Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06636552 | EUMELEIA | P2 | recruiting | An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L |
Highly Sensitized Prospective Kidney Transplant Recipients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04827979 | ATTAIN | P1/P2 | active not recruiting | Daratumumab and Belatacept for Desensitization |
Systemic Lupus Erythematosus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04810754 | DARALUP | P2 | unknown | An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus |
Lupus Nephritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04868838 | — | P2 | active not recruiting | Daratumumab to Treat Active Lupus Nephritis |
Amyloid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04270175 | — | P2 | active not recruiting | Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab |
High-risk Smoldering Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04775550 | PRISM | P2 | active not recruiting | DARA RVD For High Risk SMM |
ITP (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04703621 | — | P2 | unknown | The DART Study- Daratumumab Treatment in ITP |
Recurrent Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04230304 | — | P2 | terminated | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study |
Myeloma, Multiple (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04009109 | — | P2 | active not recruiting | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM |
POEMS Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04396496 | — | P2 | completed | Treatment of POEMS Syndrome With Daratumumab |
Refractory T-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04251065 | — | P2 | terminated | Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH |
Waldenstrom Macroglobulinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03679624 | — | P2 | terminated | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia |
Minimal Residual Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03537599 | — | P1/P2 | terminated | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant |
Alzheimer Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04070378 | DARZAD | P2 | completed | Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease |
Light Chain (AL) Amyloidosis, Stage 3B (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04131309 | AL | P2 | completed | A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis |
Smoldering Plasma Cell Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03937635 | — | P3 | recruiting | Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma |
Haematological Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04068597 | — | P1/P2 | recruiting | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies |
Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03899155 | — | P2 | recruiting | Pan Tumor Rollover Study |
Relapsed or Refractory Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03734198 | IDA53 | P2 | active not recruiting | Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction |
Multiple Myeloma Stage I (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03792620 | MAXDARA | P3 | unknown | Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation |
Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03447808 | — | P1 | completed | Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03207542 | ALL | P2 | withdrawn | Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) |
Bladder Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03473730 | — | Early P1 | completed | Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03384654 | — | P2 | completed | A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
Relapse and / or Refractory Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03143036 | — | P2 | unknown | Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma |
Breast Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03432741 | — | P1 | terminated | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer |
Newly Diagnosed Primary Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03283917 | — | P1 | active not recruiting | Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis |
Waldenström Macroglobulinemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03187262 | — | P2 | completed | A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia |
Monoclonal Gammopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03236428 | — | P2 | active not recruiting | Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma |
High Risk Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03067571 | — | P2 | terminated | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03320707 | — | P1 | completed | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants |
Membranoproliferative Glomerulonephritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03095118 | — | P2 | completed | Daratumumab in Treatment of PGNMID and C3 GN |
Advanced Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03098550 | — | P1/P2 | completed | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread |
Prostate Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03177460 | — | P1 | completed | Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer |
Malignant Neoplasms of Male Genital Organs (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03035357 | — | P2 | withdrawn | Neoadjuvant Listeria or Daratumumab in Prostate Cancer |
Myelodysplastic Syndromes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03011034 | JNJ-56022473 | P2 | completed | Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment |
Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02927925 | NKTCL | P2 | completed | A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type |
Carcinoma, Non-Small-Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03023423 | DARZALEX | P1/P2 | completed | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer |
Various Advanced Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02488759 | CheckMate358 | P1/P2 | completed | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors |
Lymphoma, Mantle-Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02413489 | — | P2 | terminated | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma |
Microsatellite Unstable Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02060188 | CheckMate142 | P2 | completed | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread |
Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01592370 | — | P1/P2 | completed | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma |
Other (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04264884 | SC | N/A | approved for marketing | Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab |
Daratumumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| AHA2023 | NCT05849740 | P4 | recruiting | Acquired Hemophilia | 25 | — |
| DARA-MVI | NCT07274462 | P4 | active not recruiting | Microvascular Inflammation - MVI in Kindey Transplant Recipients | 20 | — |
| CARTITUDE-6 | NCT05257083 | P3 | active not recruiting | Multiple Myeloma | 759 | — |
| DRAMMATIC | NCT04071457 | P3 | active not recruiting | Multiple Myeloma | 1,100 | — |
| HOVON174MM | NCT06187441 | P3 | recruiting | Multiple Myeloma | 599 | — |
| ElLen | NCT06918002 | P3 | recruiting | Multiple Myeloma, Newly Diagnosed | 824 | — |
| LINKER-MM5 | NCT07222761 | P3 | recruiting | Relapsed and/or Refractory Multiple Myeloma (RRMM) | 915 | — |
| PrE1005 | NCT07285239 | P3 | not yet recruiting | Multiple Myeloma | 500 | — |
| MajesTEC-7 | NCT05552222 | P3 | recruiting | Multiple Myeloma | 1,590 | — |
| MagnetisMM-6 | NCT05623020 | P3 | recruiting | Multiple Myeloma | 1,116 | — |
| LINKER-SMM2 | NCT07393282 | P3 | recruiting | High Risk Smoldering Multiple Myeloma (HR-SMM) | 270 | — |
| CEVOLUTION | NCT07555938 | P3 | recruiting | Multiple Myeloma | 380 | — |
| EXCALIBER-RRMM | NCT04975997 | P3 | active not recruiting | Multiple Myeloma | 939 | PMID 40346992 |
| QUINTESSENTIAL-2 | NCT06615479 | P3 | recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 440 | — |
| iMMagine-3 | NCT06413498 | P3 | recruiting | Multiple Myeloma | 450 | — |
| NDMM | NCT05561387 | P3 | recruiting | Plasma Cell Myeloma | 510 | — |
| DREAMM-10 | NCT06679101 | P3 | recruiting | Multiple Myeloma | 520 | — |
| FUMANBA-03 | NCT06464991 | P3 | recruiting | Multiple Myeloma | 240 | — |
| ALUMMINATE | NCT06232707 | P3 | withdrawn | Multiple Myeloma | 0 | — |
| DURGA-4 | NCT07391657 | P3 | recruiting | Relapsed Refractory Multiple Myeloma | 508 | — |
| Perseus | NCT03710603 | P3 | active not recruiting | Multiple Myeloma | 709 | PMID 38084760 |
| CARTITUDE-4 | NCT04181827 | P3 | active not recruiting | Multiple Myeloma | 419 | PMID 40768190 |
| MajesTEC-3 | NCT05083169 | P3 | active not recruiting | Multiple Myeloma | 587 | PMID 41363801 |
| DREAMM 7 | NCT06868667 | P3 | active not recruiting | Multiple Myeloma | 24 | — |
| DREAMM 7 | NCT06868654 | P3 | active not recruiting | Multiple Myeloma | 72 | — |
| DREAMM 7 | NCT04246047 | P3 | active not recruiting | Multiple Myeloma | 494 | PMID 40763276 |
| MonumenTAL-3 | NCT05455320 | P3 | active not recruiting | Multiple Myeloma | 864 | — |
| RADIA | NCT06867991 | P3 | recruiting | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 200 | — |
| MAGNETISMM-5 | NCT05020236 | P3 | recruiting | Multiple Myeloma | 944 | — |
| KarMMa-3 | NCT03651128 | P3 | active not recruiting | Multiple Myeloma | 381 | PMID 38651976 |
| IFM2017_03 | NCT03993912 | P3 | active not recruiting | Multiple Myeloma | 294 | PMID 41038184 |
| CONFIRM | NCT03836014 | P3 | active not recruiting | Multiple Myeloma in Relapse | 436 | — |
| AURIGA | NCT03901963 | P3 | active not recruiting | Multiple Myeloma | 200 | PMID 35985959 |
| AlloRelapseMM | NCT05675319 | P3 | terminated | Multiple Myeloma | 28 | PMID 39865222 |
| EMN14 | NCT03180736 | P3 | completed | Multiple Myeloma | 304 | PMID 37793772 |
| AL | NCT03201965 | P3 | completed | Amyloidosis | 416 | PMID 36862168 |
| DVMP | NCT02195479 | P3 | completed | Multiple Myeloma | 706 | PMID 40220771 |
| VMP | NCT03217812 | P3 | completed | Multiple Myeloma | 220 | PMID 37024420 |
| Cassiopeia | NCT02541383 | P3 | completed | Multiple Myeloma | 1,085 | PMID 38889735 |
| MAXDARA | NCT03792620 | P3 | unknown | Multiple Myeloma Stage I | 20 | PMID 7520771 |
| CANDOR | NCT03158688 | P3 | completed | Relapsed Multiple Myeloma | 466 | PMID 40087058 |
| LIGHTHOUSE | NCT04649060 | P3 | terminated | Relapsed Multiple Myeloma | 54 | PMID 37646660 |
| SUN-RAY | NCT06358638 | P2 | recruiting | Sickle Cell Disease | 12 | — |
| ELDORADO | NCT07247097 | P2 | not yet recruiting | Multiple Myeloma | 160 | — |
| FASTER | NCT06974786 | P2 | recruiting | Multiple Myeloma, Newly Diagnosed | 100 | — |
| GMMG-DADA | NCT04656951 | P2 | active not recruiting | Multiple Myeloma | 67 | — |
| IFM 2024_06 | NCT06931704 | P2 | not yet recruiting | Multiple Myeloma | 176 | — |
| ASCENT | NCT03289299 | P2 | active not recruiting | Smoldering Multiple Myeloma | 87 | — |
| Iber-KDd | NCT05896228 | P2 | recruiting | Refractory Multiple Myeloma | 30 | — |
| PRISM | NCT04775550 | P2 | active not recruiting | High-risk Smoldering Multiple Myeloma | 61 | — |
| aMMbition | NCT06577025 | P2 | active not recruiting | Multiple Myeloma | 43 | — |
| IFM2021-01 | NCT05572229 | P2 | recruiting | Multiple Myeloma | 74 | — |
| IFm2022-01 | NCT06353022 | P2 | active not recruiting | Multiple Myeloma | 103 | — |
| GEM-AnitoFIRST | NCT07045909 | P2 | recruiting | De Novo Multiple Myeloma | 30 | — |
| REVIVE | NCT06100237 | P2 | recruiting | Multiple Myeloma | 50 | — |
| DARATALL-VHR | NCT06253637 | P2 | active not recruiting | T-Lymphocytic Leukemia, Acute | 31 | — |
| HD10/DSMMXX | NCT05695508 | P2 | recruiting | Multiple Myeloma | 160 | — |
| CARTITUDE-2 | NCT04133636 | P2 | active not recruiting | Multiple Myeloma | 208 | PMID 36095849 |
| GEM-TECTAL | NCT05849610 | P2 | active not recruiting | High-Risk de Novo Multiple Myeloma | 30 | PMID 33151787 |
| EUMELEIA | NCT06636552 | P2 | recruiting | Primary Plasma Cell Leukemia | 43 | — |
| ITP | NCT07234019 | P2 | recruiting | Immune Thrombocytopenia | 160 | — |
| TALTEC | NCT06505369 | P2 | recruiting | Multiple Myeloma | 50 | — |
| T-ALL-2024 | NCT06570915 | P2 | withdrawn | ALL, Adult | 0 | — |
| ITP | NCT07362238 | P2 | recruiting | Immune Thrombocytopenia | 122 | — |
| PCL-2 | NCT05054478 | P2 | not yet recruiting | Plasma Cell Leukemia | 29 | — |
| IXA | NCT03896737 | P2 | active not recruiting | Multiple Myeloma | 401 | — |
| ITP | NCT07297563 | P2 | recruiting | Immune Thrombocytopenia | 160 | — |
| IFM 2018-04 | NCT03606577 | P2 | active not recruiting | Multiple Myeloma | 50 | PMID 38394666 |
| FIL_DALYA | NCT04915248 | P2 | recruiting | Plasmablastic Lymphoma | 28 | — |
| DPd | NCT04124497 | P2 | active not recruiting | Multiple Myeloma | 45 | — |
| DARANIVOVAX | NCT06015724 | P2 | recruiting | Pancreatic Ductal Adenocarcinoma | 54 | — |
| DAMOCLES | NCT06889948 | P2 | recruiting | Kidney Failure | 30 | — |
| ITP | NCT07362199 | P2 | recruiting | Immune Thrombocytopenia | 20 | — |
| EMN19 | NCT04166565 | P2 | active not recruiting | Multiple Myeloma | 41 | — |
| ADVANCE | NCT04268498 | P2 | active not recruiting | Multiple Myeloma | 310 | — |
| IBEX | NCT06107738 | P2 | recruiting | Multiple Myeloma | 60 | — |
| MGRS | NCT06083922 | P2 | recruiting | Multiple Myeloma | 20 | — |
| AQUARIUS | NCT05250973 | P2 | active not recruiting | Amyloidosis | 151 | — |
| ITP | NCT07063199 | P2 | recruiting | Immune Thrombocytopenia | 30 | — |
| ITP | NCT06838962 | P2 | recruiting | Immune Thrombocytopenia | 30 | — |
| SELIBORDARA | NCT03589222 | P2 | active not recruiting | Refractory Multiple Myeloma | 62 | — |
| DARA_T_ALL | NCT07021677 | P2 | recruiting | T Acute Lymphoblastic Leukemia | 18 | PMID 25999452 |
| DeRIVE | NCT03942224 | P2 | active not recruiting | Plasma Cell Myeloma | 49 | — |
| MUKnineb | NCT03188172 | P2 | unknown | Multiple Myeloma | 95 | PMID 35900614 |
| MRD | NCT04140162 | P2 | active not recruiting | Multiple Myeloma | 57 | PMID 34182226 |
| TAURUS | NCT06189833 | P2 | unknown | Multiple Myeloma | 200 | — |
| IDA53 | NCT03734198 | P2 | active not recruiting | Relapsed or Refractory Chronic Lymphocytic Leukemia | 29 | — |
| COMBAT | NCT05145296 | P2 | terminated | Sensitisation | 5 | PMID 27362308 |
| Dara-MGUS | NCT06046287 | P2 | withdrawn | Peripheral Neuropathy | 0 | — |
| POM MM 014 | NCT01946477 | P2 | completed | Multiple Myeloma | 186 | PMID 31588567 |
| AL | NCT04131309 | P2 | completed | Light Chain (AL) Amyloidosis, Stage 3B | 40 | — |
| DarPAL | NCT04895917 | P2 | terminated | AL Amyloidosis | 27 | — |
| IFM2018-01 | NCT03669445 | P2 | unknown | Multiple Myeloma | 45 | — |
| CheckMate142 | NCT02060188 | P2 | completed | Microsatellite Unstable Colorectal Cancer | 385 | PMID 28734759 |
| DARALLO | NCT04024384 | P2 | withdrawn | Multiple Myeloma | 0 | — |
| PREDATOR | NCT03697655 | P2 | unknown | Multiple Myeloma | 274 | — |
| IDARA | NCT03757221 | P2 | terminated | Multiple Myeloma | 55 | PMID 42097596 |
| DARALUP | NCT04810754 | P2 | unknown | Systemic Lupus Erythematosus | 10 | PMID 40465397 |
| DARZAD | NCT04070378 | P2 | completed | Alzheimer Disease | 16 | PMID 42063312 |
| RRMM | NCT03439293 | P2 | completed | Multiple Myeloma | 61 | PMID 38856176 |
| SY-1425 | NCT02807558 | P2 | completed | Acute Myeloid Leukemia | 155 | PMID 36477975 |
| DART4MM | NCT03992170 | P2 | unknown | Myeloma Multiple | 50 | PMID 19861683 |
| FUSIONMM-003 | NCT02807454 | P2 | terminated | Multiple Myeloma | 37 | — |
| DARIA | NCT03746652 | P2 | unknown | Multiple Myeloma | 50 | — |
| KyDaR | NCT04065789 | P2 | completed | Myeloma Multiple | 41 | PMID 33619369 |
| JNJ-56022473 | NCT03011034 | P2 | completed | Myelodysplastic Syndromes | 34 | — |
| ALL | NCT03207542 | P2 | withdrawn | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | 0 | — |
| GMMG-DANTE | NCT02977494 | P2 | completed | Multiple Myeloma | 22 | — |
| MK-3475 | NCT03221634 | P2 | withdrawn | Multiple Myeloma | 0 | — |
| DARE | NCT03450057 | P2 | completed | Relapsed/Refractory Multiple Myeloma | 38 | PMID 37340832 |
| AMYDARA | NCT02816476 | P2 | completed | Amyloidosis | 40 | — |
| IFM2014-04 | NCT02626481 | P2 | completed | Multiple Myeloma | 64 | PMID 31218679 |
| REBUILD | NCT03475628 | P2 | unknown | Multiple Myeloma | 57 | — |
| NKTCL | NCT02927925 | P2 | completed | Lymphoma | 32 | PMID 38233570 |
| FUSION-MM-005 | NCT03000452 | P2 | completed | Multiple Myeloma | 18 | — |
Terminated and withdrawn Daratumumab trials (53)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06232707withdrawnA Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT06348147withdrawnDara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
- NCT05486481withdrawnVenetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
- NCT06570915withdrawnDaratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy
- NCT07082270withdrawnSelvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
- NCT04661137suspendedA Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- NCT04230031withdrawnPhase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
- NCT05408026withdrawnStudy of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
- NCT05145296terminatedThe Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation
- NCT03622775terminatedDaratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
- NCT06046287withdrawnDaratumumab for Polyneuropathy Associated With MGUS
- NCT04824794terminatedGEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
- NCT03590652terminatedDaratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
- NCT05675319terminatedAllogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
- NCT04288765withdrawnCarfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma
- NCT04230304terminatedDaratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
- NCT04895917terminatedDaratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis
- NCT04024384withdrawnDaratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial
- NCT05556616terminatedA Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- NCT05590377terminatedA Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
- NCT03757221terminatedIxazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma
- NCT04892446terminatedStudy of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
- NCT04892264terminatedBelantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
- NCT04352205terminatedDaratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
- NCT04223661withdrawnFrailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
- NCT04700176terminatedA Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
- NCT04776018terminatedA Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT04614636terminatedFT538 in Subjects With Advanced Hematologic Malignancies
- NCT05641324terminatedA Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
- NCT05205252withdrawnA Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
- NCT04407442terminatedDaratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
- NCT04088903withdrawnStudy of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
- NCT04045028terminatedA Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- NCT04251065terminatedDaratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH
- NCT03067571terminatedDaratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT03432741terminatedDirect Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
- NCT04895410terminatedStudy to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
- NCT04956302terminatedPanobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
- NCT03837509terminatedINCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
- NCT03841565withdrawnDaratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
- NCT04649060terminatedStudy of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
- NCT03537599terminatedDaratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
- NCT03481556terminatedStudy of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
- NCT02807454terminatedA Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
- NCT04205240terminatedReduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
- NCT03207542withdrawnTrial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)
- NCT03221634withdrawnEfficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
- NCT04467281withdrawnA Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma
- NCT03679624terminatedDaratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
- NCT03701321withdrawnDaratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
- NCT03591744withdrawnDaratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
- NCT03035357withdrawnNeoadjuvant Listeria or Daratumumab in Prostate Cancer
- NCT02413489terminatedAn Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
All Daratumumab trials (347)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06358638 | SUN-RAY | Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody | P2 | recruiting | 12 | Children's National Research Institute | Apr 2024 |
| NCT07095452 | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | P2/P3 | recruiting | 660 | AbbVie | Jan 2026 | |
| NCT05257083 | CARTITUDE-6 | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma | P3 | active not recruiting | 759 | Stichting European Myeloma Network | Oct 2023 |
| NCT04071457 | DRAMMATIC | S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration | P3 | active not recruiting | 1,100 | SWOG Cancer Research Network | Aug 2019 |
| NCT07428369 | LINKER-MM8 | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) | P2/P3 | not yet recruiting | 1,570 | Regeneron Pharmaceuticals | Jun 2026 |
| NCT06187441 | HOVON174MM | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) | P3 | recruiting | 599 | Stichting Hemato-Oncologie voor Volwassenen Nederland | May 2024 |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | P3 | recruiting | 1,000 | European Myeloma Network B.V. | Dec 2025 | |
| NCT06918002 | ElLen | Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients | P3 | recruiting | 824 | Intergroupe Francophone du Myelome | Jul 2025 |
| NCT06892522 | AE | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | P1/P2 | recruiting | 440 | AbbVie | Jun 2025 |
| NCT07247097 | ELDORADO | ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma | P2 | not yet recruiting | 160 | Massachusetts General Hospital | Apr 2026 |
| NCT05907759 | Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease | P2 | recruiting | 28 | National Cancer Institute (NCI) | Jul 2024 | |
| NCT07072585 | T-ALL | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | P2/P3 | not yet recruiting | 1,708 | Children's Oncology Group | Aug 2026 |
| NCT05137054 | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | P1 | recruiting | 317 | Regeneron Pharmaceuticals | Aug 2022 | |
| NCT07222761 | LINKER-MM5 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | P3 | recruiting | 915 | Regeneron Pharmaceuticals | Jan 2026 |
| NCT07285239 | PrE1005 | Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | P3 | not yet recruiting | 500 | PrECOG, LLC. | Jul 2026 |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | P2 | recruiting | 150 | European Myeloma Network B.V. | Dec 2025 | |
| NCT07110844 | Teclistamab-Daratumumab in AL Amyloidosis | P2 | recruiting | 25 | Suzanne Lentzsch, MD | Nov 2025 | |
| NCT05552222 | MajesTEC-7 | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | P3 | recruiting | 1,590 | Janssen Research & Development, LLC | Oct 2022 |
| NCT05623020 | MagnetisMM-6 | A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | P3 | recruiting | 1,116 | Pfizer | Nov 2022 |
| NCT05259839 | IV | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma | P1 | active not recruiting | 283 | AbbVie | Oct 2022 |
| NCT07393282 | LINKER-SMM2 | A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) | P3 | recruiting | 270 | Regeneron Pharmaceuticals | May 2026 |
| NCT06974786 | FASTER | Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma | P2 | recruiting | 100 | SCRI Development Innovations, LLC | Aug 2025 |
| NCT07555938 | CEVOLUTION | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | P3 | recruiting | 380 | Hoffmann-La Roche | Jun 2026 |
| NCT07605416 | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial | P2 | not yet recruiting | 74 | National Cancer Institute (NCI) | Jul 2026 | |
| NCT04933539 | Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | P2 | active not recruiting | 14 | National Cancer Institute (NCI) | Oct 2022 | |
| NCT07075510 | Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders | P1/P2 | recruiting | 30 | University of Maryland, Baltimore | Oct 2025 | |
| NCT06182774 | Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma | P3 | recruiting | 570 | Canadian Cancer Trials Group | Apr 2024 | |
| NCT04975997 | EXCALIBER-RRMM | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | P3 | active not recruiting | 939 | Celgene | Jun 2022 |
| NCT06615479 | QUINTESSENTIAL-2 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | P3 | recruiting | 440 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Mar 2025 |
| NCT04513639 | REMNANT | The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study | P2/P3 | recruiting | 176 | Oslo University Hospital | Aug 2020 |
| NCT07029776 | MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma | P2 | not yet recruiting | 50 | University of Arkansas | Jul 2026 | |
| NCT07513129 | Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma | P1 | recruiting | 18 | M.D. Anderson Cancer Center | Jun 2026 | |
| NCT04656951 | GMMG-DADA | Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse | P2 | active not recruiting | 67 | University of Cologne | Jun 2021 |
| NCT06931704 | IFM 2024_06 | Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) | P2 | not yet recruiting | 176 | Nantes University Hospital | May 2025 |
| NCT03289299 | ASCENT | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant | P2 | active not recruiting | 87 | International Myeloma Foundation | May 2018 |
| NCT06413498 | iMMagine-3 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | P3 | recruiting | 450 | Kite, A Gilead Company | Aug 2024 |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | P2 | active not recruiting | 156 | AbbVie | Apr 2018 | |
| NCT05561387 | NDMM | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | P3 | recruiting | 510 | SWOG Cancer Research Network | Oct 2023 |
| NCT06679101 | DREAMM-10 | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | P3 | recruiting | 520 | GlaxoSmithKline | Dec 2024 |
| NCT06785415 | Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma | P1/P2 | recruiting | 37 | Mayo Clinic | Mar 2025 | |
| NCT05896228 | Iber-KDd | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | P2 | recruiting | 30 | Benjamin T Diamond, MD | Feb 2024 |
| NCT03742297 | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | P3 | active not recruiting | 462 | PETHEMA Foundation | Oct 2018 | |
| NCT06953960 | MM | A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | P1/P2 | recruiting | 199 | AbbVie | Jul 2025 |
| NCT06464991 | FUMANBA-03 | A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) | P3 | recruiting | 240 | Nanjing IASO Biotechnology Co., Ltd. | Mar 2024 |
| NCT04775550 | PRISM | DARA RVD For High Risk SMM | P2 | active not recruiting | 61 | Omar Nadeem, MD | Mar 2021 |
| NCT06022939 | Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis | P3 | recruiting | 338 | SWOG Cancer Research Network | Jul 2024 | |
| NCT06577025 | aMMbition | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 43 | Janssen Research & Development, LLC | Aug 2024 |
| NCT05572229 | IFM2021-01 | Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | P2 | recruiting | 74 | University Hospital, Lille | Dec 2023 |
| NCT06232707 | ALUMMINATE | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | P3 | withdrawn | 0 | Celgene | May 2024 |
| NCT04139304 | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | Early P1 | recruiting | 15 | AIDS Malignancy Consortium | May 2021 | |
| NCT07391657 | DURGA-4 | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) | P3 | recruiting | 508 | AstraZeneca | Feb 2026 |
| NCT06353022 | IFm2022-01 | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 103 | Nantes University Hospital | Jun 2024 |
| NCT06622005 | SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | P1 | recruiting | 15 | Roswell Park Cancer Institute | Apr 2025 | |
| NCT07221032 | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma | P1 | not yet recruiting | 12 | Medical College of Wisconsin | Jul 2026 | |
| NCT07452198 | A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma | P3 | recruiting | 358 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Mar 2026 | |
| NCT07045909 | GEM-AnitoFIRST | Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) | P2 | recruiting | 30 | PETHEMA Foundation | Jun 2025 |
| NCT03829371 | STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | P4 | active not recruiting | 450 | University of Turin, Italy | Jan 2019 | |
| NCT06100237 | REVIVE | Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) | P2 | recruiting | 50 | Carl Ola Landgren, MD, PhD | Dec 2023 |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | P1/P2 | recruiting | 128 | Indapta Therapeutics, INC. | Oct 2023 | |
| NCT05438043 | A Study of Daratumumab | P3 | recruiting | 500 | Janssen Research & Development, LLC | Dec 2022 | |
| NCT05527340 | Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. | P2 | active not recruiting | 140 | PETHEMA Foundation | Dec 2022 | |
| NCT03937635 | Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | P3 | recruiting | 288 | ECOG-ACRIN Cancer Research Group | Sep 2019 | |
| NCT04910568 | CAMMA 1 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma | P1 | active not recruiting | 126 | Genentech, Inc. | Jul 2021 |
| NCT03710603 | Perseus | Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma | P3 | active not recruiting | 709 | Stichting European Myeloma Network | Dec 2018 |
| NCT06253637 | DARATALL-VHR | Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program | P2 | active not recruiting | 31 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Oct 2024 |
| NCT05695508 | HD10/DSMMXX | GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | P2 | recruiting | 160 | University of Heidelberg Medical Center | Dec 2022 |
| NCT04133636 | CARTITUDE-2 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | P2 | active not recruiting | 208 | Janssen Research & Development, LLC | Nov 2019 |
| NCT03899155 | Pan Tumor Rollover Study | P2 | recruiting | 1,500 | Bristol-Myers Squibb | Aug 2019 | |
| NCT05849610 | GEM-TECTAL | Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma | P2 | active not recruiting | 30 | PETHEMA Foundation | Sep 2023 |
| NCT06952478 | A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | P3 | recruiting | 486 | Celltrion | Aug 2025 | |
| NCT06348147 | Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation | P2 | withdrawn | 0 | UNC Lineberger Comprehensive Cancer Center | Jul 2026 | |
| NCT07485647 | Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing | P2 | not yet recruiting | 50 | Eden Biltibo | May 2026 | |
| NCT07110662 | NET-CD38 | New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. | P1/P2 | not yet recruiting | 9 | Hospices Civils de Lyon | Oct 2025 |
| NCT04181827 | CARTITUDE-4 | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma | P3 | active not recruiting | 419 | Janssen Research & Development, LLC | Jun 2020 |
| NCT07341867 | Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | P1 | not yet recruiting | 90 | Andrew Hantel, MD | Jun 2026 | |
| NCT07335887 | Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis | P2 | not yet recruiting | 39 | Peking University People's Hospital | Jan 2026 | |
| NCT06636552 | EUMELEIA | An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L | P2 | recruiting | 43 | Hellenic Society of Hematology | Nov 2021 |
| NCT07287228 | DARA-AA-001 | The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia | P1/P2 | not yet recruiting | 37 | Institute of Hematology & Blood Diseases Hospital, China | Dec 2025 |
| NCT05486481 | ALTITUDE | Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) | P1/P2 | withdrawn | 0 | Alfred Chung, MD | Jan 2024 |
| NCT05083169 | MajesTEC-3 | A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | P3 | active not recruiting | 587 | Janssen Research & Development, LLC | Oct 2021 |
| NCT06042725 | MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | P1 | recruiting | 100 | Mayo Clinic | Mar 2024 | |
| NCT07234019 | ITP | Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | recruiting | 160 | Institute of Hematology & Blood Diseases Hospital, China | Jan 2026 |
| NCT06768489 | A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma | P1 | recruiting | 140 | Janssen Research & Development, LLC | Dec 2024 | |
| NCT06505369 | TALTEC | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | P2 | recruiting | 50 | North Estonia Medical Centre | Jun 2024 |
| NCT04972942 | ALLO-T-DART | Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma | P1 | recruiting | 30 | New York Medical College | May 2023 |
| NCT05392946 | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | P1/P2 | active not recruiting | 49 | Mayo Clinic | Aug 2022 | |
| NCT05497804 | Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | P2 | active not recruiting | 17 | Mayo Clinic | Sep 2022 | |
| NCT06570915 | T-ALL-2024 | Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy | P2 | withdrawn | 0 | Institute of Hematology & Blood Diseases Hospital, China | Dec 2025 |
| NCT05434689 | COMMANDER | COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | P1/P2 | active not recruiting | 80 | University of Alabama at Birmingham | Jan 2023 |
| NCT07018050 | Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | P2 | recruiting | 160 | Qilu Pharmaceutical Co., Ltd. | Sep 2025 | |
| NCT02773030 | A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | P1/P2 | active not recruiting | 466 | Celgene | Oct 2016 | |
| NCT06868667 | DREAMM 7 | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | P3 | active not recruiting | 24 | GlaxoSmithKline | Jul 2021 |
| NCT06868654 | DREAMM 7 | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | P3 | active not recruiting | 72 | GlaxoSmithKline | Jul 2021 |
| NCT04246047 | DREAMM 7 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | P3 | active not recruiting | 494 | GlaxoSmithKline | May 2020 |
| NCT04176718 | Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM | P2 | active not recruiting | 44 | Andrew Yee, MD | May 2020 | |
| NCT05455320 | MonumenTAL-3 | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | P3 | active not recruiting | 864 | Janssen Research & Development, LLC | Oct 2022 |
| NCT06287944 | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | P1 | recruiting | 15 | City of Hope Medical Center | Jul 2025 | |
| NCT04827979 | ATTAIN | Daratumumab and Belatacept for Desensitization | P1/P2 | active not recruiting | 19 | National Institute of Allergy and Infectious Diseases (NIAID) | Nov 2021 |
| NCT07362238 | ITP | Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) | P2 | recruiting | 122 | Institute of Hematology & Blood Diseases Hospital, China | Mar 2026 |
| NCT05054478 | PCL-2 | Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation | P2 | not yet recruiting | 29 | Assistance Publique - Hôpitaux de Paris | Oct 2021 |
| NCT06948084 | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse | P2 | not yet recruiting | 80 | National Cancer Institute (NCI) | Aug 2026 | |
| NCT07082270 | Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma | P1 | withdrawn | 0 | Roswell Park Cancer Institute | Apr 2026 | |
| NCT03896737 | IXA | Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara | P2 | active not recruiting | 401 | Stichting European Myeloma Network | Apr 2019 |
| NCT06827860 | Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | P2 | recruiting | 23 | Larysa Sanchez | Nov 2025 | |
| NCT04270175 | Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab | P2 | active not recruiting | 15 | Weill Medical College of Cornell University | Apr 2021 | |
| NCT06697483 | Risk Stratification and MRD-driven Maintenance for MM After ASCT | N/A | recruiting | 100 | Peking University People's Hospital | Dec 2024 | |
| NCT06409702 | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | P4 | recruiting | 59 | The First Affiliated Hospital of Soochow University | Jun 2024 | |
| NCT04566328 | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | P3 | recruiting | 1,450 | ECOG-ACRIN Cancer Research Group | Feb 2021 | |
| NCT04756401 | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | P2 | active not recruiting | 52 | Academic and Community Cancer Research United | Dec 2022 | |
| NCT04302324 | A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab | P2 | active not recruiting | 11 | Weill Medical College of Cornell University | Oct 2021 | |
| NCT07297563 | ITP | Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | recruiting | 160 | Institute of Hematology & Blood Diseases Hospital, China | Jan 2026 |
| NCT06867991 | RADIA | Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis | P3 | recruiting | 200 | The First People's Hospital of Changzhou | Nov 2024 |
| NCT03606577 | IFM 2018-04 | An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients | P2 | active not recruiting | 50 | Nantes University Hospital | Jul 2019 |
| NCT06142396 | Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure | Early P1 | recruiting | 30 | Augusta University | Nov 2024 | |
| NCT05849740 | AHA2023 | An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A | P4 | recruiting | 25 | Institute of Hematology & Blood Diseases Hospital, China | May 2023 |
| NCT04113018 | Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 39 | Wake Forest University Health Sciences | Jan 2020 | |
| NCT03004287 | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | P2 | active not recruiting | 50 | University of Arkansas | Jul 2017 | |
| NCT03763162 | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | P2 | active not recruiting | 40 | M.D. Anderson Cancer Center | Jan 2019 | |
| NCT06140966 | Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | P2 | recruiting | 54 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Oct 2023 | |
| NCT05050097 | MonumenTAL-2 | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | P1 | active not recruiting | 166 | Janssen Research & Development, LLC | Sep 2021 |
| NCT04722146 | MajesTEC-2 | A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | P1 | active not recruiting | 140 | Janssen Research & Development, LLC | Mar 2021 |
| NCT07274462 | DARA-MVI | DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation) | P4 | active not recruiting | 20 | University Hospital, Martin | Nov 2025 |
| NCT03556332 | A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation | P2 | active not recruiting | 41 | Memorial Sloan Kettering Cancer Center | Jul 2018 | |
| NCT04915248 | FIL_DALYA | Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. | P2 | recruiting | 28 | Fondazione Italiana Linfomi - ETS | Jul 2022 |
| NCT04124497 | DPd | A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients | P2 | active not recruiting | 45 | Fondazione EMN Italy Onlus | Jul 2019 |
| NCT06015724 | DARANIVOVAX | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | P2 | recruiting | 54 | Georgetown University | Jan 2024 |
| NCT06889948 | DAMOCLES | The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland | P2 | recruiting | 30 | Helsinki University Central Hospital | Jan 2024 |
| NCT05289687 | Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL | P2 | recruiting | 20 | Eastern Cooperative Oncology Group | May 2023 | |
| NCT04009109 | Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | P2 | active not recruiting | 79 | Alliance Foundation Trials, LLC. | Oct 2020 | |
| NCT05020236 | MAGNETISMM-5 | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | P3 | recruiting | 944 | Pfizer | Oct 2021 |
| NCT03283917 | Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis | P1 | active not recruiting | 21 | M.D. Anderson Cancer Center | Feb 2018 | |
| NCT02343042 | STOMP | Selinexor and Backbone Treatments of Multiple Myeloma Patients | P1/P2 | active not recruiting | 300 | Karyopharm Therapeutics Inc | Oct 2015 |
| NCT03651128 | KarMMa-3 | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | P3 | active not recruiting | 381 | Celgene | Apr 2019 |
| NCT04108195 | A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | P1 | active not recruiting | 290 | Janssen Research & Development, LLC | Feb 2020 | |
| NCT07362199 | ITP | Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | P2 | recruiting | 20 | Institute of Hematology & Blood Diseases Hospital, China | Mar 2026 |
| NCT06398457 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | Early P1 | recruiting | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2024 | |
| NCT06192979 | Optimize First-line Treatment for AL Amyloidosis With t (11; 14) | N/A | recruiting | 41 | Jin Lu, MD | Jan 2024 | |
| NCT05671757 | DARE-APS | Daratumumab in Primary Antiphospholipid Syndrome | P1/P2 | recruiting | 22 | National Institute of Allergy and Infectious Diseases (NIAID) | May 2023 |
| NCT04166565 | EMN19 | Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease | P2 | active not recruiting | 41 | Stichting European Myeloma Network | Oct 2019 |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | P1/P2 | recruiting | 250 | CellCentric Ltd. | Aug 2019 | |
| NCT05363111 | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | P1 | recruiting | 15 | City of Hope Medical Center | Nov 2022 | |
| NCT04661137 | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | P2 | suspended | 96 | Hackensack Meridian Health | Mar 2021 | |
| NCT07085728 | Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure | P2 | active not recruiting | 74 | Eastern Cooperative Oncology Group | Aug 2025 | |
| NCT04268498 | ADVANCE | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma | P2 | active not recruiting | 310 | University of Miami | Feb 2020 |
| NCT04230031 | Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma | P2 | withdrawn | 0 | Wake Forest University Health Sciences | Jul 2021 | |
| NCT07081126 | DARTABMR | Daratumumab for Late Antibody-Mediated Rejection | N/A | recruiting | 20 | University Hospital, Martin | Jul 2025 |
| NCT06107738 | IBEX | Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma | P2 | recruiting | 60 | Barbara Ann Karmanos Cancer Institute | Dec 2023 |
| NCT04922723 | PRIDE | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma | P1/P2 | active not recruiting | 16 | West Virginia University | Oct 2022 |
| NCT05888870 | ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor | P4 | recruiting | 50 | Institute of Hematology & Blood Diseases Hospital, China | Nov 2023 | |
| NCT05898646 | Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial | P2 | recruiting | 96 | Mayo Clinic | Jul 2023 | |
| NCT04925193 | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | P2 | active not recruiting | 18 | University of Colorado, Denver | Nov 2021 | |
| NCT04973605 | BGB-11417 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | P1/P2 | recruiting | 246 | BeOne Medicines | Sep 2021 |
| NCT03989414 | RRMM | A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | P1/P2 | active not recruiting | 424 | Celgene | Sep 2019 |
| NCT07026604 | CCM-DS01 | Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study | Early P1 | not yet recruiting | 10 | Beijing Tiantan Hospital | Jul 2025 |
| NCT06083922 | MGRS | A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) | P2 | recruiting | 20 | Memorial Sloan Kettering Cancer Center | Oct 2023 |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | P1/P2 | not yet recruiting | 48 | Hellenic Society of Hematology | Oct 2022 | |
| NCT05139225 | A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma | P1 | active not recruiting | 7 | Memorial Sloan Kettering Cancer Center | Oct 2021 | |
| NCT05250973 | AQUARIUS | A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis | P2 | active not recruiting | 151 | Janssen Research & Development, LLC | Mar 2022 |
| NCT06629818 | Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) | P2 | recruiting | 36 | Peking Union Medical College Hospital | Oct 2024 | |
| NCT03993912 | IFM2017_03 | Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy | P3 | active not recruiting | 294 | University Hospital, Lille | Oct 2019 |
| NCT03236428 | Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma | P2 | active not recruiting | 42 | Dana-Farber Cancer Institute | Nov 2017 | |
| NCT07015021 | DKPD | The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients | N/A | not yet recruiting | 72 | The First Affiliated Hospital of Soochow University | Jun 2025 |
| NCT06169215 | Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 70 | National Cancer Institute (NCI) | Jul 2024 | |
| NCT05451771 | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | P1/P2 | recruiting | 53 | Rajshekhar Chakraborty, MD | Oct 2022 | |
| NCT04868838 | Daratumumab to Treat Active Lupus Nephritis | P2 | active not recruiting | 12 | Mayo Clinic | Apr 2021 | |
| NCT03290950 | A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 69 | Memorial Sloan Kettering Cancer Center | Sep 2017 | |
| NCT07063199 | ITP | Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) | P2 | recruiting | 30 | Institute of Hematology & Blood Diseases Hospital, China | Aug 2025 |
| NCT06838962 | ITP | Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) | P2 | recruiting | 30 | Institute of Hematology & Blood Diseases Hospital, China | Aug 2024 |
| NCT05654506 | Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits | P2 | recruiting | 40 | Mayo Clinic | Aug 2023 | |
| NCT05300451 | Daratumumab in HLA Desensitization Prior to Transplantation | P2 | enrolling by invitation | 10 | Barry A. Boilson | Mar 2022 | |
| NCT04497961 | A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide | P2 | active not recruiting | 95 | Memorial Sloan Kettering Cancer Center | Aug 2020 | |
| NCT03589222 | SELIBORDARA | SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | P2 | active not recruiting | 62 | PETHEMA Foundation | Jul 2018 |
| NCT07021677 | DARA_T_ALL | Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" | P2 | recruiting | 18 | Tata Memorial Centre | Aug 2023 |
| NCT04635189 | Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma | P2 | active not recruiting | 28 | University of Rochester | Jul 2021 | |
| NCT03836014 | CONFIRM | Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | P3 | active not recruiting | 436 | Assistance Publique - Hôpitaux de Paris | Jul 2019 |
| NCT03942224 | DeRIVE | Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 49 | Emory University | Jul 2019 |
| NCT03346135 | Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma | P2 | active not recruiting | 31 | City of Hope Medical Center | Jul 2019 | |
| NCT03500445 | Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | P2 | active not recruiting | 75 | University of Chicago | Feb 2019 | |
| NCT06483139 | Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy | — | recruiting | 450 | Brigham and Women's Hospital | Jun 2024 | |
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 73 | US Oncology Research | Sep 2021 | |
| NCT04052880 | Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | P2 | active not recruiting | 17 | Larysa Sanchez | Oct 2019 | |
| NCT03188172 | MUKnineb | MUK Nine b: OPTIMUM Treatment Protocol | P2 | unknown | 95 | University of Leeds | Sep 2017 |
| NCT03901963 | AURIGA | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant | P3 | active not recruiting | 200 | Janssen Research & Development, LLC | Apr 2019 |
| NCT03447808 | Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | P1 | completed | 15 | Jennifer Woyach | Aug 2018 | |
| NCT04151667 | Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 33 | H. Lee Moffitt Cancer Center and Research Institute | Nov 2019 | |
| NCT03301220 | A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma | P3 | completed | 390 | Janssen Research & Development, LLC | Nov 2017 | |
| NCT04140162 | MRD | Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy | P2 | active not recruiting | 57 | University of Michigan Rogel Cancer Center | Oct 2020 |
| NCT04667663 | CPD-DARA | CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. | P1 | active not recruiting | 16 | Cancer Trials Ireland | Dec 2021 |
| NCT03652064 | A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | P3 | completed | 395 | Janssen Research & Development, LLC | Nov 2018 | |
| NCT05776940 | Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis | P3 | unknown | 116 | Air Force Military Medical University, China | Mar 2023 | |
| NCT05280275 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | P1/P2 | unknown | 36 | Hellenic Society of Hematology | Apr 2022 | |
| NCT04814615 | A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma | P2 | unknown | 60 | Hoag Memorial Hospital Presbyterian | Mar 2021 | |
| NCT05408026 | PVD-DARA | Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM | P1/P2 | withdrawn | 0 | Alliance Foundation Trials, LLC. | Oct 2022 |
| NCT06549634 | Biomarkers of AKI in Patients Receiving Daratumumab | — | completed | 20 | Brigham and Women's Hospital | Sep 2024 | |
| NCT06297681 | Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease | — | unknown | 40 | Beijing Chao Yang Hospital | Mar 2024 | |
| NCT06189833 | TAURUS | Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS | P2 | unknown | 200 | Stichting European Myeloma Network | Nov 2023 |
| NCT05857982 | Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | P1/P2 | unknown | 20 | Second Affiliated Hospital of Soochow University | May 2023 | |
| NCT05562882 | A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia | P2 | unknown | 60 | Institute of Hematology & Blood Diseases Hospital, China | Dec 2022 | |
| NCT05308654 | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | P1 | active not recruiting | 34 | AbbVie | May 2022 | |
| NCT03734198 | IDA53 | Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction | P2 | active not recruiting | 29 | French Innovative Leukemia Organisation | Dec 2018 |
| NCT05403138 | DAWN | Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders | P2/P3 | active not recruiting | 135 | Tianjin Medical University General Hospital | Nov 2022 |
| NCT01665794 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | P1/P2 | completed | 25 | University of Chicago | Aug 2012 | |
| NCT05807048 | Daratumumab in STK11 Mutated NSCLC | P2 | completed | 8 | NYU Langone Health | Jun 2023 | |
| NCT05218603 | MM | Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT | — | unknown | 100 | PETHEMA Foundation | Nov 2021 |
| NCT05145296 | COMBAT | The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation | P2 | terminated | 5 | University Hospital, Grenoble | Jan 2022 |
| NCT03622775 | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant | P2 | terminated | 13 | M.D. Anderson Cancer Center | Apr 2019 | |
| NCT05561049 | Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma | — | unknown | 120 | The First Affiliated Hospital of Soochow University | Oct 2022 | |
| NCT06046287 | Dara-MGUS | Daratumumab for Polyneuropathy Associated With MGUS | P2 | withdrawn | 0 | Georgetown University | Sep 2025 |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | P1/P2 | terminated | 130 | Genmab | Mar 2021 | |
| NCT06055075 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | P1/P2 | completed | 19 | Hoffmann-La Roche | Dec 2023 | |
| NCT03590652 | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma | P2 | terminated | 23 | University of California, San Diego | Oct 2018 | |
| NCT01946477 | POM MM 014 | Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting | P2 | completed | 186 | Celgene | May 2014 |
| NCT01415882 | Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib | P2 | completed | 165 | Mayo Clinic | Jan 2012 | |
| NCT03477539 | Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma | P2 | completed | 49 | Mayo Clinic | Apr 2018 | |
| NCT05675319 | AlloRelapseMM | Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy | P3 | terminated | 28 | Universitätsklinikum Hamburg-Eppendorf | Mar 2023 |
| NCT06455748 | Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study | N/A | recruiting | 20 | Yongyong MA | Mar 2024 | |
| NCT05704400 | Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome | P2 | unknown | 20 | Istituto Giannina Gaslini | Mar 2023 | |
| NCT04288765 | Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma | P3 | withdrawn | 0 | Grupo Cooperativo de Hemopatías Malignas | Mar 2020 | |
| NCT04230304 | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study | P2 | terminated | 8 | Mayo Clinic | Nov 2020 | |
| NCT05835726 | DILEMMA | Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. | — | completed | 188 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Jan 2022 |
| NCT04131309 | AL | A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis | P2 | completed | 40 | Stichting European Myeloma Network | Sep 2019 |
| NCT03473730 | Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | Early P1 | completed | 17 | M.D. Anderson Cancer Center | May 2018 | |
| NCT04895917 | DarPAL | Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis | P2 | terminated | 27 | Fondazione IRCCS Policlinico San Matteo di Pavia | Jun 2021 |
| NCT05088330 | A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM | N/A | unknown | 76 | The First Affiliated Hospital of Soochow University | Dec 2021 | |
| NCT04703621 | The DART Study- Daratumumab Treatment in ITP | P2 | unknown | 21 | Ostfold Hospital Trust | Jan 2021 | |
| NCT03732703 | MyDRUG | Myeloma-Developing Regimens Using Genomics (MyDRUG) | P1/P2 | completed | 103 | Multiple Myeloma Research Consortium | Apr 2019 |
| NCT03669445 | IFM2018-01 | Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma | P2 | unknown | 45 | University Hospital, Toulouse | Dec 2018 |
| NCT05832216 | Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia | P1 | completed | 10 | Institute of Hematology & Blood Diseases Hospital, China | Apr 2023 | |
| NCT03180736 | EMN14 | Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex | P3 | completed | 304 | Stichting European Myeloma Network | Jun 2017 |
| NCT02076009 | A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | P3 | completed | 569 | Janssen Research & Development, LLC | Jul 2014 | |
| NCT03201965 | AL | A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis | P3 | completed | 416 | Janssen Research & Development, LLC | Oct 2017 |
| NCT01615029 | Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma | P1/P2 | completed | 45 | Janssen Research & Development, LLC | Jun 2012 | |
| NCT02060188 | CheckMate142 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | P2 | completed | 385 | Bristol-Myers Squibb | Mar 2014 |
| NCT05182073 | FT576 in Subjects With Multiple Myeloma | P1 | completed | 31 | Fate Therapeutics | Nov 2021 | |
| NCT04714372 | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia | P1 | completed | 9 | Masonic Cancer Center, University of Minnesota | Nov 2021 | |
| NCT02252172 | Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma | P3 | completed | 737 | Janssen Research & Development, LLC | Feb 2015 | |
| NCT05004259 | DARA-AIHA | The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia | P1 | completed | 2 | Dartmouth-Hitchcock Medical Center | Mar 2022 |
| NCT05284591 | MYLENE | Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv) | — | completed | 96 | iOMEDICO AG | Jul 2022 |
| NCT05913596 | The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation | N/A | unknown | 15 | First Affiliated Hospital of Zhejiang University | May 2023 | |
| NCT02195479 | DVMP | A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | P3 | completed | 706 | Janssen Research & Development, LLC | Dec 2014 |
| NCT04024384 | DARALLO | Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial | P2 | withdrawn | 0 | Assistance Publique - Hôpitaux de Paris | Jul 2019 |
| NCT03697655 | PREDATOR | Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma | P2 | unknown | 274 | Polish Myeloma Consortium | Dec 2018 |
| NCT05243342 | A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma | P1 | completed | 18 | Genentech, Inc. | Apr 2022 | |
| NCT01592370 | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | P1/P2 | completed | 320 | Bristol-Myers Squibb | Aug 2012 | |
| NCT05556616 | iinnovate-2 | A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma | P1 | terminated | 15 | Teva Branded Pharmaceutical Products R&D LLC | Jan 2023 |
| NCT02316106 | A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma | P2 | completed | 123 | Janssen Research & Development, LLC | May 2015 | |
| NCT05590377 | iinnovate-3 | A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma | P1/P2 | terminated | 15 | Teva Branded Pharmaceutical Products R&D LLC | Jan 2023 |
| NCT05511428 | Home Based Daratumumab Administration for Patients With Multiple Myeloma | P4 | completed | 20 | Thomas Jefferson University | Nov 2022 | |
| NCT03695744 | Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma | P2 | unknown | 27 | Singapore General Hospital | Oct 2019 | |
| NCT03757221 | IDARA | Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma | P2 | terminated | 55 | University Hospital, Caen | Feb 2019 |
| NCT04892446 | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | P2 | terminated | 36 | Gilead Sciences | Nov 2021 | |
| NCT03412565 | A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | P2 | completed | 265 | Janssen Research & Development, LLC | Apr 2018 | |
| NCT04474938 | Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis | P2 | unknown | 40 | Peking Union Medical College Hospital | May 2021 | |
| NCT04892264 | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | P1 | terminated | 5 | Mayo Clinic | Jun 2021 | |
| NCT03217812 | VMP | A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) | P3 | completed | 220 | Janssen Research & Development, LLC | Nov 2017 |
| NCT03234972 | A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | P3 | completed | 213 | Janssen Research & Development, LLC | Nov 2017 | |
| NCT03177460 | Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer | P1 | completed | 33 | M.D. Anderson Cancer Center | Jun 2017 | |
| NCT04610320 | Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation | P1 | completed | 8 | Ronald Witteles | Jul 2021 | |
| NCT03184194 | Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide | P2 | completed | 62 | Amsterdam UMC, location VUmc | Feb 2018 | |
| NCT04352205 | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | P2 | terminated | 17 | Emory University | May 2020 | |
| NCT01998971 | A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | P1 | completed | 240 | Janssen Research & Development, LLC | Feb 2014 | |
| NCT02136134 | Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | P3 | completed | 498 | Janssen Research & Development, LLC | Aug 2014 | |
| NCT04223661 | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy | P2 | withdrawn | 0 | Attaya Suvannasankha | Dec 2021 | |
| NCT04810754 | DARALUP | An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus | P2 | unknown | 10 | Charite University, Berlin, Germany | Jun 2021 |
| NCT04700176 | A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma | P2 | terminated | 1 | Hackensack Meridian Health | May 2022 | |
| NCT04304144 | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | P2 | completed | 25 | Alexion Pharmaceuticals, Inc. | Mar 2020 | |
| NCT04776018 | RRMM | A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) | P1/P2 | terminated | 27 | Takeda | Apr 2021 |
| NCT04396496 | Treatment of POEMS Syndrome With Daratumumab | P2 | completed | 2 | University of Arkansas | Sep 2020 | |
| NCT04121260 | A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma | P1 | completed | 21 | Janssen Research & Development, LLC | Dec 2019 | |
| NCT02541383 | Cassiopeia | A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma | P3 | completed | 1,085 | Intergroupe Francophone du Myelome | Sep 2015 |
| NCT04070378 | DARZAD | Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease | P2 | completed | 16 | Marc L Gordon, MD | Nov 2019 |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | P1 | terminated | 42 | Fate Therapeutics | Oct 2020 | |
| NCT05641324 | OMNIA-2 | A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | P1 | terminated | 4 | Anaveon AG | Feb 2023 |
| NCT05205252 | ARIA | A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. | P1/P2 | withdrawn | 0 | Epizyme, Inc. | Dec 2021 |
| NCT03439293 | RRMM | A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) | P2 | completed | 61 | Takeda | Mar 2018 |
| NCT03311828 | Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma | P1 | completed | 12 | City of Hope Medical Center | Feb 2018 | |
| NCT04204980 | DARDAR | Desensitization in Kidney Allograft Using Daratumumab | P1/P2 | completed | 21 | Assistance Publique - Hôpitaux de Paris | Feb 2020 |
| NCT04407442 | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab | P2 | terminated | 5 | University of California, San Francisco | Nov 2020 | |
| NCT04136756 | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | P1 | completed | 30 | Nektar Therapeutics | Oct 2019 | |
| NCT02519452 | A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | P1 | completed | 120 | Janssen Research & Development, LLC | Oct 2015 | |
| NCT04088903 | Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation | P1 | withdrawn | 0 | Ronald Witteles | Apr 2021 | |
| NCT04045028 | PK | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | P1 | terminated | 41 | Genentech, Inc. | Jul 2019 |
| NCT03490344 | Short Course Daratumumab in Patients With Multiple Myeloma | P2 | completed | 10 | Memorial Sloan Kettering Cancer Center | May 2018 | |
| NCT02807558 | SY-1425 | A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome | P2 | completed | 155 | Syros Pharmaceuticals | Sep 2016 |
| NCT03992170 | DART4MM | Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive | P2 | unknown | 50 | Azienda Ospedaliera Universitaria Senese | Dec 2018 |
| NCT03012880 | Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma | P2 | completed | 80 | Mayo Clinic | Apr 2017 | |
| NCT04251065 | Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH | P2 | terminated | 8 | Fondazione Italiana Linfomi - ETS | Sep 2020 | |
| NCT03067571 | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | P2 | terminated | 7 | M.D. Anderson Cancer Center | Oct 2017 | |
| NCT02488759 | CheckMate358 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors | P1/P2 | completed | 578 | Bristol-Myers Squibb | Oct 2015 |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | P1 | terminated | 17 | Mayo Clinic | Mar 2018 | |
| NCT03384654 | A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | P2 | completed | 47 | Janssen Research & Development, LLC | May 2018 | |
| NCT03768960 | A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent | P4 | completed | 150 | Johnson & Johnson Private Limited | Jun 2019 | |
| NCT03143036 | Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma | P2 | unknown | 100 | National University Hospital, Singapore | May 2018 | |
| NCT04895410 | IV | Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma | P1 | terminated | 8 | AbbVie | Jan 2022 |
| NCT04956302 | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | P1 | terminated | 1 | Abdullah Khan | Sep 2021 | |
| NCT03792620 | MAXDARA | Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation | P3 | unknown | 20 | Grupo de Estudos Multicentricos em Onco-Hematologia | Nov 2018 |
| NCT03158688 | CANDOR | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. | P3 | completed | 466 | Amgen | Jun 2017 |
| NCT02874742 | Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma | P2 | completed | 224 | Janssen Research & Development, LLC | Aug 2016 | |
| NCT03837509 | SC | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | P1/P2 | terminated | 15 | Incyte Corporation | Sep 2019 |
| NCT04280328 | Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | P1 | completed | 7 | Corvus Pharmaceuticals, Inc. | Feb 2020 | |
| NCT03841565 | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | P2 | withdrawn | 0 | Academic and Community Cancer Research United | Aug 2020 | |
| NCT04649060 | LIGHTHOUSE | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma | P3 | terminated | 54 | Oncopeptides AB | Dec 2020 |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | P1/P2 | terminated | 4 | Sumithira Vasu | Jan 2020 | |
| NCT03481556 | ANCHOR | Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM | P1/P2 | terminated | 56 | Oncopeptides AB | Apr 2018 |
| NCT02807454 | FUSIONMM-003 | A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma | P2 | terminated | 37 | Celgene | Jul 2016 |
| NCT03746652 | DARIA | Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | P2 | unknown | 50 | Hellenic Society of Hematology | Dec 2018 |
| NCT03187262 | A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia | P2 | completed | 13 | Dana-Farber Cancer Institute | Nov 2017 | |
| NCT03697629 | A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma | P2 | completed | 40 | Canadian Myeloma Research Group | Dec 2018 | |
| NCT04205240 | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma | P2 | terminated | 1 | Srinivas Devarakonda | Dec 2020 | |
| NCT03357952 | A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | P2/P3 | completed | 10 | Janssen Research & Development, LLC | Nov 2017 | |
| NCT04065789 | KyDaR | Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | P2 | completed | 41 | Tel-Aviv Sourasky Medical Center | May 2018 |
| NCT03011034 | JNJ-56022473 | Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment | P2 | completed | 34 | Janssen Research & Development, LLC | Feb 2017 |
| NCT03207542 | ALL | Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Jul 2018 |
| NCT02977494 | GMMG-DANTE | Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment | P2 | completed | 22 | Universitätsklinikum Hamburg-Eppendorf | Jun 2016 |
| NCT03221634 | MK-3475 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) | P2 | withdrawn | 0 | Merck Sharp & Dohme LLC | Aug 2017 |
| NCT03450057 | DARE | Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment | P2 | completed | 38 | Hellenic Society of Hematology | Feb 2018 |
| NCT02431208 | MM | A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) | P1 | completed | 85 | Hoffmann-La Roche | Jul 2015 |
| NCT04467281 | A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma | P2 | withdrawn | 0 | Memorial Sloan Kettering Cancer Center | Jun 2020 | |
| NCT02955810 | CyBorD-Dara | Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) | P1 | unknown | 18 | National University of Ireland, Galway, Ireland | Nov 2016 |
| NCT02816476 | AMYDARA | Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis | P2 | completed | 40 | University Hospital, Limoges | Sep 2016 |
| NCT03679624 | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia | P2 | terminated | 1 | Weill Medical College of Cornell University | Jul 2020 | |
| NCT02951819 | A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma | P2 | completed | 101 | Janssen Scientific Affairs, LLC | Nov 2016 | |
| NCT02841033 | Daratumumab for the Treatment of Patients With AL Amyloidosis | P1/P2 | completed | 22 | Boston Medical Center | Mar 2017 | |
| NCT03098550 | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | P1/P2 | completed | 105 | Bristol-Myers Squibb | Jun 2017 | |
| NCT03701321 | Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | P1/P2 | withdrawn | 0 | National Cancer Institute (NCI) | Jan 2019 | |
| NCT03095118 | Daratumumab in Treatment of PGNMID and C3 GN | P2 | completed | 12 | Fernando Fervenza | Sep 2017 | |
| NCT03665155 | First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody | P1/P2 | completed | 11 | Memorial Sloan Kettering Cancer Center | Sep 2018 | |
| NCT02918331 | A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation | P1 | completed | 7 | Janssen Pharmaceutical K.K. | Sep 2016 | |
| NCT02626481 | IFM2014-04 | Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma | P2 | completed | 64 | University Hospital, Lille | Dec 2015 |
| NCT03475628 | REBUILD | Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma | P2 | unknown | 57 | Hellenic Society of Hematology | Feb 2018 |
| NCT04264884 | SC | Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab | — | approved for marketing | 0 | Janssen Research & Development, LLC | — |
| NCT02927925 | NKTCL | A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type | P2 | completed | 32 | Janssen Research & Development, LLC | Feb 2017 |
| NCT02852837 | Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy | P1 | completed | 50 | Janssen Research & Development, LLC | Sep 2016 | |
| NCT03591744 | Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia | P1 | withdrawn | 0 | City of Hope Medical Center | Oct 2018 | |
| NCT03023423 | DARZALEX | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer | P1/P2 | completed | 100 | Janssen Research & Development, LLC | Dec 2016 |
| NCT03320707 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants | P1 | completed | 66 | Janssen Research & Development, LLC | Oct 2017 | |
| NCT03068351 | BET | Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma | P1 | completed | 24 | Hoffmann-La Roche | Jun 2017 |
| NCT03035357 | Neoadjuvant Listeria or Daratumumab in Prostate Cancer | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Mar 2017 | |
| NCT02497378 | A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma | P1 | completed | 8 | Janssen Pharmaceutical K.K. | Jul 2015 | |
| NCT03000452 | FUSION-MM-005 | A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | P2 | completed | 18 | Celgene | Mar 2017 |
| NCT02944565 | Daratumumab in Treating Patients With Multiple Myeloma | P2 | completed | 28 | Ohio State University Comprehensive Cancer Center | Feb 2017 | |
| NCT02413489 | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma | P2 | terminated | 36 | Janssen Research & Development, LLC | Sep 2015 | |
| NCT01985126 | An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD | P2 | completed | 124 | Janssen Research & Development, LLC | Sep 2013 | |
| NCT00574288 | Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma | P2 | completed | 104 | Janssen Research & Development, LLC | Mar 2008 | |
| NCT02419118 | DARA | "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab " | P2/P3 | completed | 4 | Vejle Hospital | Jan 2015 |
| NCT02116569 | A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | P1 | completed | 9 | Janssen Pharmaceutical K.K. | Apr 2014 | |
| NCT02477891 | Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma | — | approved for marketing | 0 | Janssen Research & Development, LLC | — |
Daratumumab clinical trials: frequently asked questions
- How many Daratumumab clinical trials are there?
- 347 Daratumumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 86 are actively recruiting participants. 85 are marked completed.
- Are Daratumumab clinical trials recruiting in 2026?
- Yes — 86 Daratumumab trials are actively recruiting in 2026, with 1512 U.S. sites across 50 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Daratumumab being studied for?
- Daratumumab is being studied for Multiple Myeloma, Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Multiple Myeloma, AL Amyloidosis and 246 more. The trials are grouped by indication on this page.
- What phase is Daratumumab in?
- Daratumumab clinical trials span 7 Phase 4, 57 Phase 3, 161 Phase 2, 52 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Daratumumab clinical trials?
- The lead sponsor across the most Daratumumab trials is Janssen Research & Development, LLC, with 170 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Daratumumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: